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Mammalian blood cell production is maintained by a heterogenous hematopoietic 
stem cell (HSC) population with remarkable capacity for self-renewal and 
pluripotency. While bone marrow is the major site for HSC residence, the red pulp 
region of the spleen can also act as a niche for HSC, despite the lack of osteoblasts. 
HSC differentiation in bone marrow is influenced by signals imposed by the stromal 
niche. It is therefore important to consider how the splenic niche might signal 
hematopoiesis and how spleen-resident HSC might contribute to hematopoiesis in 
the steady-state and also across the life span of the animal. Hematopoiesis in spleen 
is commonly linked to stress and disease, a phenomenon termed extramedullary 
hematopoiesis. However, no studies have yet addressed lineage output in steady-
state spleen. Evidence from in vitro studies and in vivo models of extramedullary 
hematopoiesis suggest that spleen-resident HSC might be primed for myeloid cell 
production.  
Transplantation studies performed to address the precise hematopoietic potential of 
spleen HSC under physiological conditions have been hampered by the limitation of 
using traditional conditioning methods to ablate HSC niches. Clearance of HSC 
niches is required for donor engraftment to occur. With success with dietary-based 
HSC niche clearance techniques which are non-inflammatory, the study of steady-
state hematopoiesis specific to the spleen is now possible. Here we attempt to 
address spleen-specific steady-state hematopoiesis using valine-restricted dietary 
conditioning, so removing the need for irradiation therapy prior to HSC 
transplantation. Following optimization of a dietary-based conditioning regime to 
clear HSC niches, donor chimerism was achieved within both the spleen and bone 
marrow, so demonstrating the potential value of this model particularly in regard to 





Published lineage commitment models describing hematopoiesis are controversial 
and still incomplete in predicting how fate-decision occurs. Current models fall short 
of describing the symmetry by which HSC progress through lineage commitment, 
and whether there are defining genes or imprinted epigenetic programs driving the 
various differentiation pathways at particular periods during life. For example, 
myeloid-biased CD150hi HSC appear increasingly with age, evident by an 
imbalance in myeloid and lymphoid cell development. Given that HSC localized in 
spleen reflect cells with myeloid-restricted potential, this study considers how the 
spleen contributes to the age-associated decline in balanced lineage output 
potential.  
The overall hypothesis of this thesis is that HSC differentiation in spleen under 
steady-state conditions is biased towards myelopoiesis, and that throughout adult 
aging, the spleen microenvironment continually imprints myeloid bias into HSC 
programming, therefore contributing to a rise in myeloid-biased HSC numbers. The 
first aim of this study is to address these unknown gaps in research by optimizing a 
new transplant pre-conditioning method that maintains the host steady-state 
condition in order to study the spleen-specific contribution to hematopoiesis. These 
results then complement the second aim which is to investigate the role of spleen in 
the age-associated dominance of myeloid-biased HSC.  
Optimization of valine-restriction preconditioning found that mice fed a valine-
deficient diet for three weeks tolerated immediate complete diet reintroduction.  By 
allowing 2-days of valine reintroduction prior to transplantation it was found that 
donor cell engraftment could be achieved. We suggest that cell-dose titration is 
necessary to enhance donor engraftment since valine-restriction preconditioning 
does not clear hematopoietic niches entirely. Results of investigation of the second 
aim indicate that spleen does not play a significant role in the progressive myeloid-
biased HSC shift over an animal’s lifetime. However, no firm conclusion can be 




thesis does not show conclusively that spleen contributes to the accumulation of 
myeloid-biased HSC over age. Optimization of a dietary-based preconditioning 
method will assist future investigation into the hematopoietic contribution of spleen 
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1.1 Hematopoietic Stem Cells 
1.2.1 Heterogeneity 
 
In mammals, HSC are responsible for complete blood cell production during 
embryonic development which continues throughout adulthood. The ability of HSC 
to propagate production of all blood cell types can now be defined by key 
characteristics that distinguish those stem cells (Ng & Alexander, 2017). HSC have 
functional capacity for hematopoiesis, producing a complex hematopoietic hierarchy 
of quiescent, repopulating and self-renewing stem cells, multi-potential progenitor 
cells, lineage committed progenitors, and mature erythroid, myeloid and lymphoid 
blood cells (Ito & Frenette, 2016). Phenotyping and in vivo repopulation assays have 
been used effectively to divide the HSC compartment into long term (LT) and short 
term (ST) repopulating HSC (Osawa, Hanada, Hamada, & Nakauchi, 1996). LT-HSC 
are found in the bone marrow environment in niches existing under relatively hypoxic 
conditions (Nombela-Arrieta et al., 2013). LT-HSC give rise to lifelong production of 
lymphoid and myeloerythroid lineages after transplantation into lethally irradiated 
recipients (Christensen & Weissman, 2001). Their direct progeny are phenotypically 
and transcriptionally distinct ST-HSC (Dykstra et al., 2007), which have more limited 
self-renewing capacity than LT-HSC, but can still produce a transient wave of 
hematopoietic reconstitution giving rise to all blood lineages for ~8-12 weeks in 
murine hosts (Christensen & Weissman, 2001; Sawai et al., 2016). Multipotent 
progenitors (MPP) are functionally similar to ST-HSC, although they are known to 
have less proliferative potential (Dykstra et al., 2007). 
 
1.2.2 LT-HSC Subsets and Differentiation 
 
Historically, LT-HSC were considered to be a biologically homogenous population of 
stem cells (Dykstra et al., 2007). However, it is now accepted that they are a 
heterogeneous population (Christensen & Weissman, 2001; Kiel et al., 2005; Seita 




of multiple functional and behavioural properties, including size, self-renewal 
capacity, cell cycle status, differentiation capacity, surface molecule expression and 
lifespan (Christensen & Weissman, 2001; Ema, Morita, & Suda, 2014). The 
differentiative potential of cells within the HSC compartment is now a topic of 
rigorous investigation. In particular, the analysis of serially transplanted adult HSC 
have been reported to propagate distinct patterns of differentiation (Benz et al., 2012; 
Dykstra et al., 2007; Kent et al., 2009; Morita, Ema, & Nakauchi, 2010).  
 
Recent lineage reconstitution assays in mice transplanted with cultured or freshly 
purified adult bone marrow cells now confirm that individual HSC have distinct 
differentiation capacities. The results of these studies have led to newly coined terms 
describing HSC with a bias towards either myeloid lineage, lymphoid lineage, or a 
balance of both lineages (Muller-Sieburg, Cho, Karlsson, Huang, & Sieburg, 2004). 
Durable self-renewal activity, but variable lymphopoietic activity in HSC, was first 
described as “myeloid-biased” and “balanced” in a study by Muller-Sieburg et al. 
(2004). Analysis was based on the measurement of the clonally-derived myeloid to 
lymphoid cell ratio in the peripheral blood of transplant recipients (Muller-Sieburg et 
al., 2004). Within the context of defining HSC as myeloid-biased and balanced, 
alternative terms are now used to describe slightly different HSC subtypes, which 
reflect a more precise classification (Benz et al., 2012). This classification compares 
clonal contribution of isolated stem cells to the total peripheral blood lymphoid and 
myeloid compartment. This circumvents the impact of host-specific variation on 
those values, as well as adjusts the calculation for defining lymphoid and myeloid 
ratios. These alternative terms are -HSC (also known as My-bi HSC), -HSC 
(balanced) and - and -HSC (Lymphoid-biased) (Figure 1.2.1) (Beerman et al., 





Figure 1.2.1  Differentiation classification of repopulating HSC from single-
cell transplantation studies in mice.  
Individual HSC have distinct differentiation capacities leading to new terms which 
describe repopulation potential and differentiation hierarchy. Within the grey box is 
the four cell types with long-term (>16 weeks) repopulating activity.  cells represent 
the LT-HSC with a strong propensity for myelopoiesis which can be independently 
and exclusively sustained as well as contribute to lymphoid repopulating potential.  
cells are self-renewing LT-HSC with balanced lymphopoiesis and myelopoiesis 
output potential while - and -HSC are derived from  and  HSC and contribute 
mostly toward lymphopoiesis. Dotted lines suggest lineage contribution is minimal 
and thick lines suggest main pathway of contribution (Dykstra et al., 2007).  
 
 
In a long term (≥16weeks) analysis of clonal progeny generated in irradiated mice 
transplanted with 352 single cells, or their immediate 4-day progeny, four distinct 
repopulation patterns arising from transplanted single cells were detected in the host 
(Dykstra et al., 2007). These included the previously introduced  and  HSC, as 
well as  and  type HSC (Figure 1.2.1) (Dykstra et al., 2007). The  and  patterns 




the original  and  repopulation pattern amongst their progeny (Benz et al., 2012; 
Dykstra et al., 2007). The  and  patterns appeared to be closely related to ST 
repopulating cells (ST-HSC and MPP), but display multipotency and contribute to 
the circulating WBC pool for up to 16 weeks, distinguishing  and  from ST-HSC. 
The decline in their repopulating activity suggests exhaustion of self-renewal 
capacity within 6-7 months, identifying an intermediate stage of repopulating cells 
arising from  cells (Dykstra et al., 2007; Ema et al., 2014; Morita et al., 2010). In 
light of these recent findings on heterogeneity within murine HSC in terms of 
behavioural and differentiative capacity, the hierarchical model of the mouse 
hematopoietic system is now in dispute.  
 
The classical differentiation model describes the stepwise, symmetrical and linear 
branching of cells that make up the hematopoietic system, initiated by HSC (LT then 
ST) within the top tier of the model (Akashi, Traver, Miyamoto, & Weissman, 2000; 
Kondo, Weissman, & Akashi, 1997; Reya, Morrison, Clarke, & Weissman, 2001). 
Phenotypically, HSC are contained within the cell fraction devoid of mature cell 
lineage markers, otherwise known as lineage negative (Lin-) hematopoietic cell 
population. These are marked by expression of two common markers, Sca-1 and 
the cKit tyrosine kinase receptor. All three phenotypes are typically combined and 
referred as LSK (Spangrude, Heimfeld, & Weissman, 1988). The classical model 
defines three hematopoietic cell types that align with the LSK phenotype: LT-HSC, 
ST-HSC and MPP. To distinguish between LT-HSC and ST-HSC, one can use the 
CD34 marker of ST-HSC and other downstream progenitors (Figure 1.2.2.A). CD34 
is a transmembrane phosphoglycoprotein that was first identified on HSC, but is not 
a specific marker and is also expressed by many other cells unrelated to the 






 Figure 1.2.2 Classical differentiation and myeloid-bypass differentiation 
hierarchy. 
Two varying models of HSC differentiation in the murine hematopoietic system. The 
dark grey box defines the HSC compartment and light grey defines MPP 
compartment in both models. A) Classical differentiation hierarchy is adapted from 
Shao et al. (2013) showing symmetrical differentiation. B) the myeloid-bypass model 
is adapted from Yamamoto et al. (2013) and Nimmo, May, and Enver (2015) showing 
myeloid restricted progenitors (MyRP) within the HSC compartment containing some 
potential for self-renewal. The lymphoid-primed multipotent progenitor (LMPP) lacks 
repopulating ability and stems from ST-HSC rather than MPP. The dotted line 
indicates a bypass pathway for megakaryocyte differentiation. Wide heterogeneity 
is known within the HSC compartment and is depicted with distinct LT-HSC clones 
at the hierarchy’s apex. 
 
The signaling lymphocyte activation molecule (SLAM) family markers can be used 
to definitively separate HSC subsets in mice. SLAM molecules comprise the family 
of CD150, CD48, CD229 and CD224 that regulate proliferation and activation of 
lymphocytes (Kiel et al., 2005). These are type I transmembrane receptors broadly 













































marker of HSC that has gained wide adoption is CD150, a member of the SLAM 
family (Oguro, Ding, & Morrison, 2013; Wilson et al., 2015). Expression of CD150 
and CD48 can be used in conjunction with the LSK phenotype to distinguish LT-
HSC, ST-HSC and MPP.  It is known that the LSK/CD34-CD150+CD48- subset is 
enriched for LT-HSC, the LSK/CD34+CD150+CD48- subset is enriched for ST-HSC, 
and the LSK/CD34+CD150+/lo/-CD48+ subset is enriched for MPP (Kiel et al., 2005; 
Oguro et al., 2013). The classical hierarchical model for hematopoiesis also 
describes differentiation of MPP giving rise to oligopotent lineage-committed 
progenitors with both lymphoid and myeloid committed progenitors (Akashi et al., 
2000). However, with MPP now known to be heterogeneous (Yamamoto et al., 
2013), such a direct differentiation model towards committed progenitor production 
is now thought to be a simplification of many more comprehensive and complex 
pathways (Ema et al., 2014; Woolthuis & Park, 2016). 
 
1.2.3 Evolving Models for HSC Differentiation 
 
As more information on HSC heterogeneity is uncovered, the more complex the 
differentiation of HSC to blood cells appears to become (Adolfsson et al., 2005; 
Morita et al., 2010). For perspective, over the past 3 decades several hierarchy 
models have been proposed, including the stochastic model (Ogawa, Porter, & 
Nakahata, 1983), a model based on transcription factors (Singh, 1996), alternative 
and composite model (Adolfsson et al., 2005), the myeloid-bypass model (Figure 
1.2.2B) (Yamamoto et al., 2013) and the newly suggested platelet-biased model 
(Kovtonyuk, Fritsch, Feng, Manz, & Takizawa, 2016). Similarities between the 
composite, alternative and myeloid-bypass model involve the deviation from ST-
HSC towards a lymphoid-primed multipotent progenitor (LMPP) and a myeloid 
progenitor that may have distinct megakaryocyte/erythroid potential. The myeloid-
bypass model suggests that a myeloid-restricted progenitor (MyRP) exists within the 
CD34- HSC compartment which can self-renew and supply the majority of the of 




Long-term multilineage reconstitution of lethally irradiated murine bone marrow from 
individual purified HSC or limiting doses of whole bone marrow transplants reveal 
this functional heterogeneity within HSC.  
 
HSC heterogeneity, LT-repopulating capacity and HSC age can all be examined 
through measurement of CD150 expression (Beerman et al., 2010; Kiel et al., 2005; 
Morita et al., 2010). A study by Morita et al. (2010) transplanted single CD150high, 
CD150medium and CD150negative CD34-LSK cells into primary recipients and found 
repopulating activity was detected in all fractions, suggesting repopulating potential 
in the primary recipient is relatively equal amongst CD150+/-CD34-LSK cells. 
However, secondary transplantation of only CD150highCD34-LSK cells exhibited LT-
repopulating potential. Consistent with other studies, CD150highCD34-LSK cells 
predominantly reconstituted myeloid lineages, whereas CD150negativeCD34-LSK cells 
reconstituted lymphoid lineages and CD150mediumCD34-LSK cells intermediately 
reconstituted both myeloid and lymphoid lineages in a pattern in between CD150high 
and CD150negative activity (Morita et al., 2010). Furthermore, Beerman et al. (2010) 
competitively transplanted 10 or 50 purified aged (24-month-old) murine HSC and 
reported predominantly myeloid-biased reconstitution, in contrast to recipients 
transplanted with young (4-month-old) HSC. Beerman et al. (2010) further reported 
that the majority of aged HSC with increased myeloid-biased potential also 
expressed CD150 in high amounts, which is consistent with the results of Morita et 
al. (2010).  
 
One limitation of the Beerman et al. (2010) study is the transplantations of multiple 
HSC as opposed to single cell transplants. Single cell transplants identify the rare 
HSC that may be CD150high but produce a low level of primary myeloid-reconstitution 
and sustain multilineage secondary reconstitution (Morita et al., 2010). In contrast, 
bulk HSC transplantation can mask and neglect the contribution of heterogeneous 
cells within a theoretically pure and highly enriched HSC population. Surprising and 




now suggest that a platelet-biased HSC sit at the apical of the hematopoietic 
hierarchy (Sanjuan-Pla et al., 2013). Platelet-biased HSC express the blood plasma 
glycoprotein, von Willebrand factor, and can give rise to platelets and erythroid 
lineages earlier than other lineages and so generate both myeloid- and lymphoid-
biased HSC (Grover et al., 2016; Kovtonyuk et al., 2016; Sanjuan-Pla et al., 2013). 
This heterogeneity within highly conserved classical progenitors suggests that an 
alternative lineage commitment pathway is at work. Advances in single-cell analysis 
provide a pathway to study heterogeneity and fate-mapping processes within a cell 
population. 
 
1.2.4 Lineage Commitment 
 
Commitment is the irreversible point at which the cell becomes restricted in its 
potential to differentiate into any other cell type. HSC are multipotent, and able to 
form many cell types, while myeloid and lymphoid progenitors are historically 
considered restricted to producing myeloid or lymphoid lineage cells. An 
understanding of how HSC differentiate into different cell types and how they attain 
their various functions has clinical significance. It was previously thought that lineage 
commitment occurred at the lineage-restricted progenitor level, rather than at the 
level of the HSC (Cavazzana-Calvo et al., 2011). However, extensive self-renewal 
capacity and the ability to reconstitute all mature cells, albeit at different lengths of 
time, are characteristics that set lineage-biased HSC apart from lineage restricted 
progenitors (Muller-Sieburg, Sieburg, Bernitz, & Cattarossi, 2012).  
 
HSC have long been assumed to be epigenetically primed to give equal probability 
in differentiation. However, variation in mature blood cell populations produced from 
individual HSC has now been characterized (Beerman et al., 2010; Challen, Boles, 
Lin, & Goodell, 2009; Copley & Eaves, 2013; Morita et al., 2010). Single-cell imaging 
and tracking methods are firmly established for observing cell differentiation, lineage 




technology to study continuous long-term single-cell blood generation (Cao et al., 
2004; Eilken, Nishikawa, & Schroeder, 2009),  co-regulation of transcription factors 
in differentiation dynamics of single-HSC (Hoppe et al., 2016), and real-time early 
dynamics of hematopoietic reconstitution in live animals (Cao et al., 2004). Each of 
these studies cannot conclude definitively whether intrinsic or extrinsic mechanisms 
are responsible for lineage-commitment but rather a multitude of extracellular signals 
activating upstream regulators of lineage-specific transcription factors (Eilken et al., 
2009; Hoppe et al., 2016; Krause et al., 2001). It is clear that mechanisms that drive 
cell fate decision for lineage commitment are crucial to understanding the 
development of blood malignancies and the age-associated decline of a balanced 
hematopoietic output. 
 
1.3 The Aging HSC 
 
Hematopoietic aging is driven by  intrinsic and extrinsic factors that leads to a 
decrease in immune response (Linton & Dorshkind, 2004) and  regenerative capacity 
(Ergen & Goodell, 2010; Florian et al., 2012), and an increase in myeloid cell 
proliferative diseases (Kiss, Sabry, Lazarus, & Lipton, 2007). Multiple studies 
analysing the murine hematopoietic system over age have reported a progressive 
increase in myeloid cells and a decrease in erythropoiesis and T and B cell 
production (Beerman et al., 2010; Florian et al., 2012). Functional changes within 
the HSC compartment have been reported as contributors to the decline of balanced 
HSC differentiation (Beerman & Rossi, 2014). Studies using limiting dilution 
transplant HSC assays confirmed a functional heterogeneity amongst the conserved 
HSC subtypes found in the bone marrow of young mice (Beerman et al., 2010; 
Dykstra et al., 2007). HSC which exhibit preference toward myeloid lineage 
differentiation represented <25% of LT-HSC in young mice, but gradually increased 
following normal physiological aging (Beerman et al., 2010). Lineage-biased HSC 
subsets could also be isolated from both young and old mice based on differential 




side population CD150hi) cells presented a functional capacity for myeloid-bias upon 
transplantation. This suggested that differential CD150 expression was a defining 
and reliable marker for HSC heterogeneity (Challen et al., 2009). Major alterations 
in functionality and molecular regulatory pathways commonly identified across HSC 
aging studies include lineage-biased clonal composition (Beerman et al., 2010), cell 
polarity changes (Florian et al., 2012), epigenetic dysregulation induced by 
increased inflammation (Chambers et al., 2007), increased levels of radical oxygen 
species (ROS) (Ito et al., 2006), and accumulation of DNA damage (Rossi et al., 
2007; Wang et al., 2012). The factors contributing to intrinsic and extrinsic 
mechanisms of HSC aging, age-associated progression of lineage-bias, and the 
functional changes of HSC with age, are considered further below. 
 
1.3.1 Intrinsic Mechanisms 
 
It is understood that HSC aging could be driven by both cell-intrinsic mechanisms 
(eg. epigenetic preprograming) and cell-extrinsic (eg. environmental-, cytokine- and 
stress- mediated) mechanisms. A key hallmark of HSC aging is the gradual 
predominance of myeloid differentiation, although the mechanism behind this 
progressive lineage-biased skewing is unknown, whether spleen contributes to this 
age-related change is addressed in this study. Hematopoietic stem cells are capable 
of sustaining lifelong blood cell production, and repeated serial transplantation 
shows that HSC can outlive their original donor. Other studies however report 
evidence of HSC exhaustion (Harrison, 1979) perhaps due to telomere loss during 
cell division (Kamminga et al., 2005; Van Zant, de Haan, & Rich, 1997). 
Heterogeneity within the HSC compartment is well known, and lifespan of HSC is 
also a heterogeneous characteristic detected in all clonal analyses (Muller-Sieburg 
et al., 2004; C. Muller-Sieburg & Sieburg, 2008; Sieburg et al., 2006). More recent 
analysis of the intrinsic nature of changes in LT-HSC during age includes altered 
lineage potential, whereby genes responsible for function and specification were 




(CD150hi) within the myeloid compartment (Beerman et al., 2010; Morita et al., 2010; 
Rossi et al., 2005).  
 
1.3.2 Extrinsic Mechanisms  
 
Aging is a risk factor for myeloproliferative diseases such as leukaemia, and studies 
have suggested that the niche environment that HSC interact with, and not only cell-
intrinsic mechanisms, have the capacity to shift lineage output as we age under a 
dominant CD150hi HSC clone (Vas, Senger, Dorr, Niebel, & Geiger, 2012). Serial 
HSC transplant assays have been used as a model to study stem cell aging, 
shedding light on the reconstitution kinetics and lineage-commitment preference of 
aging HSC. The Beerman et al. (2010) study showed that CD150lo balanced HSC 
became progressively more myeloid-biased with each successive round of 
transplantation so that by the third transplant 88% of recipients displayed myeloid-
biased reconstitution patterns similar to reconstituted old transplanted HSC. This 
suggests that the spleen niche impacted the behaviour of the HSC long after they 
had left the niche. Furthermore, the study detailed that there were no differences 
observed between CD150hi and CD150lo HSC in cell cycle activity. These data 
together suggest that CD150hi HSC do not progressively dominate the HSC 
compartment over time due to and increased rate of cycling but through another 
mechanism in the spleen. 
 
Bone marrow HSC which enter the spleen adopt a pre-activated cell cycle status 
allowing HSC in the spleen to quickly enter the cell cycle for fast hematopoietic 
response (Coppin et al., 2018). This suggests that the spleen microenvironment, not 
only varies to that of the bone marrow microenvironment, but does indeed instruct 
HSC to behave differently. One major stromal cell that bone marrow has and spleen 
lacks is osteoblasts. A study showed that loss of osteoblasts induced dramatic 
hematopoietic alterations, including decreased bone marrow hematopoiesis and 




myeloid compartment (Visnjic et al., 2004). Alterations in signaling can be linked with 
decreased bone formation and osteopontin secretion, increased adipogenesis, 
changes in extracellular matrix, tissue structure damage and receptor insensitivity, 
all of which contribute to an aging-associated decline in HSC (Guidi et al., 2017). 
How the spleen contributes to hematopoiesis has only been studied in diseased 
conditions, but in each of these studies the spleen is found to be a niche with the 
capacity to prime HSC for myeloid response (Bronte & Pittet, 2013; Robbins et al., 
2012; Wu et al., 2018). 
 
1.4 Hematopoiesis in the Spleen 
 
HSC in the spleen are rare, however transplanted HSC isolated from the spleen 
display long term reconstitution potential (Wolber et al., 2002). Since HSC are known 
to enter blood circulation in steady-state (Wright, Wagers, Gulati, Johnson, & 
Weissman, 2001), it is no surprise that the spleen hosts a small population of HSC 
which contribute to erythropoiesis, alongside bone marrow HSC (Dzierzak & 
Philipsen, 2013; Yanai, Satoh, & Obinata, 1991). However, the splenic niche and 
bone marrow niche are quite different, and therefore spleen-specific hematopoiesis 
is presumably distinct. For example, spleen lacks the presence of osteoblastic cells, 
which play a key role in maintaining non-dividing HSC, or quiescence, in the bone 
marrow (Calvi et al., 2003). Likewise, HSC in the spleen are reported to be 
phenotypically distinct and exist in a pre-activated state, allowing spleen-derived 
HSC to respond to emergency signals quicker by entering cell cycle, compared to 
the more quiescent HSC counterpart in bone marrow (Coppin et al., 2018). However, 
hematopoiesis in spleen remains difficult to analyse.  
 
1.4.1 Pre-conditioning for HSC Transplant 
 
Current methods for transplantation of HSC requires niche clearance to provide the 




permanently damages bone marrow microenvironment (Abbuehl, Tatarova, Held, & 
Huelsken, 2017) which is also required for cell signaling and engraftment for HSC 
reconstitution. Irradiation damage subsequently initiates systemic inflammatory 
responses and perhaps augments the true behavioral profile of HSC reconstitution. 
Moreover, hematopoiesis in bone marrow has been more widely studied than in the 
spleen, and hematopoiesis in the spleen during steady-state is even more enigmatic. 
 
Transplantation studies addressing the precise function of spleen during steady-
state hematopoiesis have been hampered by limitations in traditional HSC 
conditioning. A recent study proposed novel niche clearance methods that allow a 
promising future for steady-state hematopoiesis studies. Taya et al. (2016) 
suggested that selectively restricting the essential amino acid, valine, from the diet 
for a small period of time significantly decreased the number of host HSC. Complete 
blood counts from mice fed valine restricted diets for 4 weeks showed marked 
reduction in WBC, and RBC, whereas platelet counts, bone marrow T cells and 
megakaryocyte-erythroid progenitor cells were unaffected. Depletion of valine from 
the diet appears to reduce the number of lifelong side effects typically experienced 
from chemotherapy and irradiation as myeloablative treatments. Such side effects 
include growth retardation, infertility, and significantly shorter lifespan (<1-year post-
transplant). The integrity of the splenic niche structure during valine restriction to 
achieve HSC depletion is yet to be studied. One systemic effect of the valine 
restriction was splenic atrophy. However, spleen rapidly reverted to normal size, 
evident by a gain of splenic red and white pulp, once a complete diet was resumed 
(Taya et al., 2016). The Taya et al. study reported good engraftment (>1% donor 
chimerism) from 5 x103 transplanted donor LSK cells and 1x107 transplanted donor 
bone marrow cells (2016). Valine restriction may offer a promising look into spleen 






1.4.2 Extramedullary Hematopoiesis 
 
Extramedullary hematopoiesis (EMH) is the production of blood cells outside of the 
medullar of the bone marrow cavity, where hematopoiesis typically occurs. It is 
trilineage, meaning it gives rise to each of the myeloid, lymphoid and erythroid 
lineages. However, it has been reported that a particular lineage or cell type may 
dominate, depending on the underlying pathogenesis (Johns & Christopher, 2012). 
Studies on prevalence and cell production during extramedullary hematopoiesis are 
limited, partly due to the perception that it is an epiphenomenon or state which is 
secondary to a primary condition of inflammation, infection, myeloproliferative 
disease, or physiological stress (Johns & Christopher, 2012). This leads to the 
migration of HSC into the spleen where they undergo hematopoiesis in sinusoidal 
niches (Inra et al., 2015) and contribute to blood cell production (Bronte & Pittet, 
2013; Wright et al., 2001). Nevertheless, EMH in the spleen contributes to disease 
pathogenesis for conditions like atherosclerosis (Robbins et al., 2012; Tall & Yvan-
Charvet, 2015), acute myocardial infarction (Kim, Kim, Kang, & Seo, 2014; 
Thackeray et al., 2015) and myeloproliferative diseases (Prakash et al., 2012; Song, 
Park, & Uhm, 2018).The conditions are not yet understood (Johns & Christopher, 
2012). 
 
Extramedullary hematopoiesis develops in spleen during pregnancy, induced by an 
increase in estrogen levels in females (Nakada et al., 2014). Pregnant mice display 
significantly increased cellularity, erythropoiesis and myelopoiesis in spleen, as well 
as increased numbers of HSC (Nakada et al., 2014). Following deletion of the Esr1 
gene responsible for estrogen production, pregnant mice showed a reduction in 
pregnancy-associated hematopoiesis and HSC numbers, but no change in HSC 
frequency in bone marrow. Esr1 deletion was also associated with reduced cellularity 
and erythropoiesis in spleen (Nakada et al., 2014). This finding indicated mobilization 




pregnancy (Nakada et al., 2014). Alternatively, Esr1 could control HSC proliferation, 
rather than mobilization of HSC from bone marrow towards the spleen. A recent 
study demonstrated that expression of transcription factor Tlx1 on splenic stromal 
cells are required for mobilizing HSC into the spleen during extramedullary 
hematopoiesis (Oda et al., 2018). Interestingly, Oda et al. reported that the 
overexpression of Tlx1 was sufficient to induce extramedullary hematopoiesis, 
without any additional stimulating factors (2018). The human spleen in pregnancy is 
less studied. However, an increase in spleen cellularity, erythropoiesis and overall 
size during human pregnancy is consistent with murine studies (Maymon et al., 
2006). Here, pregnancy is used as an inducible model for studying extramedullary 
hematopoiesis in spleen. 
Evidence from in vitro studies (O'Neill et al., 2004) and in vivo models of 
extramedullary hematopoiesis (Coppin et al., 2018; Nakada et al., 2014; Swirski & 
Robbins, 2013) suggests that spleen-resident HSC are primed for myeloid cell 
production. This is shown by atherosclerosis studies which report that approximately 
50% of myeloid cells are produced by spleen (Swirski & Robbins, 2013).  In 
myocardial infarction (MI) increased total myeloid cells have been reported in 
spleens of mice (Coppin et al., 2018). Moreover, splenic HSC exhibit a pre-activated, 
with splenic HSC readily in G1 cell cycle phase in the steady-state condition, as 
opposed to bone marrow HSC which are robustly retained in a quiescent G0 phase 
(Coppin et al., 2018). More interestingly, when pre-activated HSC in spleen mobilize 
back to bone marrow, the HSC are able to resume the quiescent G0 state (Coppin 
et al., 2018). Taken together, the spleen is known to, 1) favor myelo- and erythro-
poiesis in stressed or inflammatory conditions, 2) maintain HSC in a pre-activated 
state, and pregnancy can increase HSC mobilization into the spleen which in turn 
increases hematopoiesis. Therefore, the spleens role in age-related myeloid-biased 
HSC differentiation can be assessed by inducing multiple cycles of pregnancy as a 




1.4.3 Spleen in Mice and Humans 
 
The spleen acts as an accessory organ in both humans and mice during stress-
induced or diseased states (Dor et al., 2006; Nakada et al., 2014). In contrast, 
hematopoiesis under physiological steady-state conditions remains poorly 
understood. In rodents, the spleen acts largely as a site for erythropoiesis (Yanai et 
al., 1991) and megakaryocytopoiesis (Slayton et al., 2002), and an important filter 
for turnover of red blood cells.  Most studies on spleen as a hematopoietic organ 
involve the murine model, which has similarities with human spleen in terms of 
immune cell development and function, although structural differences involving the 
marginal zone, the ratio of white and red pulp, and the vasculature are apparent 
(Mebius & Kraal, 2005; O’Neill, 2012; Steiniger, 2015). As a site for steady-state 
extramedullary hematopoiesis, both murine and human spleen remain poorly 
investigated in terms of HSC development during adult ontogeny. Splenectomy in 
murine models was once thought to have no impact on hematopoietic development. 
However, recent in vitro studies may indicate an important function for spleen in 
myelopoiesis, with evidence of spleen endothelial cells supporting the presence of a 
specific dendritic-like cell progenitor endogenous to the spleen (Bronte & Pittet, 
2013; Tan & O'Neill, 2012). The spleen is a secondary lymphatic organ, that lacks 
afferent lymphatics, facilitating leukocyte collection directly from the blood and is thus 
important in immunity to bacterial infections (Steiniger, 2015). A consequence of 
splenectomy in human patients is increased susceptibility to infection with 
encapsulated bacteria like Streptococcus pneumoniae, Neisseria meningitidis and 
Hemophilus influenza type B, thus demonstrating how the spleen serves to protect 
the human body (Brendolan, Rosado, Carsetti, Selleri, & Dear, 2007; Bronte & Pittet, 
2013).  
 
Murine spleen offers a unique perspective into the mechanisms that govern HSC 
development, however reports replicating and translating murine research into 




comparing human and porcine spleen reported human spleen cells giving rise to 
multiple hematopoietic colonies, but only when EMH was evident (Dor et al., 2006). 
The pig spleen, although it is larger than human spleen (by an average of 4g/kg body 
weight), appears to hold HPC in similar number to primate spleen, which is similar 
to human spleen. Although the primate spleen results were described as preliminary, 
they suggested human adult spleens may be equally a source of early HPC, or even 
HSC, that may prove of clinical use (Dor et al., 2006). Some similarities with age-
associated changes found in both mice and humans exist, including increased 
incidence of myeloproliferative disorders, progressive decline in lymphopoiesis and 
rise in dominance toward myeloid-biased HSC differentiation, suggesting 
hematopoietic aging is an evolutionary conserved process (Muller-Sieburg et al., 
2012; Pang et al., 2011). Humans also present with splenomegaly during pregnancy, 
suggesting increased cellularity in the spleen, as does in murine spleen during 
pregnancy (Nakada et al., 2014). Thus, murine studies have been an essential 







Hematopoietic stem cells (HSC) are responsible for mammalian blood cell 
production. As adult stem cells, they are equipped with the remarkable capacity for 
self-renewal and multi-potency. While most of the adult HSC population resides and 
develops within the bone marrow niche, a smaller population of HSC has been 
identified within the spleen of several animal models (Dor et al., 2006; Wolber et al., 
2002). Hematopoiesis within the spleen is commonly associated with stress or 
disease and is referred to as extramedullary hematopoiesis (Johns & Christopher, 
2012). This can occur when bone marrow is compromised due to an inflammatory 
response or disease and cannot meet increased hematopoietic demand. One 
example is leukaemia, where the medullary cavity of bone marrow becomes 
overcrowded with immature white blood cells and reduces the capacity for normal 
hematopoiesis (Johns & Christopher, 2012).  
 
Little is known about HSC differentiation in spleen, the precise function of spleen in 
steady-state hematopoiesis, or how hematopoiesis in spleen contributes to changes 
in cell differentiation associated with age and disease. Spleen-specific 
hematopoiesis varies from that of bone marrow in terms of the HSC activation state 
(Coppin et al., 2018), and hematopoietic output under in vitro conditions (O’Neill, 
2012). However, it has been difficult to determine the precise lineage output of 
differentiating HSC in the spleen in situ, especially under physiological conditions. 
HSC transplantation studies require conditioning methods to clear stem cell niches 
in order for transplanted HSC to engraft. More specifically, these conditioning 
regimes typically involve full-body lethal irradiation which generates systemic 
inflammation. Recently, a dietary-based method of HSC niche clearance that does 
not stimulate an inflammatory response was described (Taya et al., 2016). This 
method now permits the study of steady-state hematopoiesis in spleen following 





An understanding of hematopoiesis due to splenic HSC has further implications in 
terms of whether spleen specifically contributes to myeloid-bias amongst HSC and 
hence the aging HSC phenotype. Evidence from in vitro studies (O'Neill et al., 2004) 
and in vivo models of extramedullary hematopoiesis (Nakada et al., 2014) suggests 
that spleen-resident HSC are ‘primed’ for myeloid cell production. Furthermore, the 
shift towards myeloid-biased differentiation has already been shown to increase with 
age (Balazs, Fabian, Esmon, & Mulligan, 2006; Beerman et al., 2010; Morita et al., 
2010). Investigations into the cause of this shift focused on HSC intrinsic or extrinsic 
factors, with a clear knowledge gap surrounding the influence of the spleen 
microenvironment on HSC differentiation. Recent studies report that the expression 
of cell surface marker CD150 is higher on aged myeloid-biased HSC (Beerman et 
al., 2010; Morita et al., 2010). In addition, an imbalance in myeloid-biased CD150hi 
HSC is evident with age. By comparing the expression level of the CD150 marker 
on the surface of HSC in normal aged mice and normally aged splenectomised mice, 
one can assess the contribution of spleen to the accumulation of CD150hi myeloid-
biased HSC. Furthermore, exbreeder mice that have gone through multiple cycles 
of pregnancy-induced extramedullary hematopoiesis can be used as a model for the 
contribution of extramedullary hematopoiesis in spleen towards increasing myeloid-






1.6 Aims  
 
The specific aims of this study are: 
1. To determine the steady-state lineage output of HSC which differentiate in 
spleen. 





A knowledge of how the splenic niche signals HSC will provide insight into 
extramedullary hematopoiesis and its relationship with disease. The prevalence, 
distribution and molecular basis of extramedullary hematopoiesis in spleen is 
important for a complete understanding of hematopoiesis during aging and disease. 
In this study, we firstly hypothesize that lineage output in spleen under steady-state 
conditions predominantly involves myeloid and erythroid lineages. The contribution 
of spleen under steady-state condition towards the development of myeloid and 
erythroid lineages will impact our understanding of HSC fate mapping, and could 
direct understanding away from the classic symmetrical differentiation model (Akashi 
et al., 2000; Kondo et al., 1997), towards models based on single cell studies, such 
as the myeloid-bypass model (Nimmo et al., 2015; Yamamoto et al., 2013). Our 
second hypothesis predicts that the absence of a spleen in both aging and pregnant 
animal models will lead to a decrease in myeloid-bias amongst LT-HSC. The 
significance of such a finding is that the splenic niche would contribute to the 
progressive age-associated myeloid-biased differentiation and would drive the aging 

















Adult male and female C57BL/6JArc (C57BL/6J), adult female B6.SJL-
PtprcaPepcb/BoyJArc (B6.SJL) and adult female BALB/cARC (BALB/c) mice were 
purchased from the Animal Resource Centre (ARC; Perth, Western Australia, 
Australia) and held at the Bond University animal holding facility for experimentation. 
Mice were sacrificed via cervical dislocation. All mice were handled and housed 
according to protocols approved by the University of Queensland Animal Ethics 
Committee (Approval number: BOND/453/15/ARC/NHMRC). 
 
Cell preparation 
Cells were isolated from the spleen, bone marrow or peripheral blood. Bone marrow 
was collected from the femur and tibia of each leg by flushing into ice-cold phosphate 
buffer solution (PBS) (Thermo Fisher, Waltham, MA, USA) using a 26G hypodermic 
needle (Terumo, NSW Australia). Spleen was harvested and placed in ice-cold PBS. 
Approximately 1mL of peripheral blood was collected via retro-orbital bleeding using 
a 1.1mm x 75mm capillary micro-haematocrit tube (heparinized) (Thomas Scientific, 
New Jersey, USA), and collecting flow-through in 1mL Titertube micro test tubes 
(Biorad, CA, USA). Solid tissues were coarsely crushed through a wire sieve using 
a 5mL syringe plunger (Livingstone International, NSW, Australia) and transferred 
into a 14mL Falcon tube (BD, San Jose, USA) for centrifugation (200xg for 5 minutes, 
4°C) (Heraus Megafuge 40R Centrifuge series; Thermo Fisher, Waltham, MA, USA). 
After discarding the supernatant (SN), cells were resuspended in red blood cell 
(RBC) lysis buffer (NH4Cl, 0.017M Tris-base [pH7.5]) (eBioscience, San Diego, CA, 
USA) at 1mL buffer/organ, or 5mL lysis buffer/1mL whole blood. Cells were 
incubated for 10 minutes at room temperature (RT) and then washed with 10mL ice-
cold PBS and centrifuged. The supernatant was discarded, and the cell pellet 
resuspended in 1ml FACS buffer (PBS/2%BSA/0.01%NaN3). The cells were then 
filtered through a 70µm single cell strainer (Greiner Bio-One, Kremsmunster, 





Magnetic cell separation 
To enrich cell preparations for HSC isolation, mature lineage-positive cells were first 
magnetically depleted. A cocktail of lineage-specific biotinylated antibodies was 
used for depletion of mature cells (refer to Table 2.1 for antibody list). Antibodies 
were specific for the mature cell markers: CD3 (T cells), CD11c (dendritic cells), 
CD19 (B cells), Gr-1 (monocytes and neutrophils), CD48 (T/B/myeloid cells) and 
NK1.1 (natural killers and T cell subsets). Anti-lineage antibody cocktails that label 
up to 107 cells were prepared by adding 1 µL of each antibody and 1µL of Fc Block 
(FcBl) to cells in a total volume of 100 µL FACS buffer. Cells were mixed and 
incubated with antibodies on ice for 10 minutes before washing with 5ml FACS 
buffer. After centrifugation and discard of SN, the cells were resuspended and 
incubated with anti-biotin MACS® Ultra-pure Microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) at 20µL/107 cells for 10 minutes on ice. Cells were 
resuspended in 2mL FACS buffer and transferred to a 5mL Falcon round bottom 
tube (StemCell Technologies, Vancouver, Canada). Tubes were placed into an 
EasySep Magnet (single 5mL tube holding capacity; StemCell Technologies, 
Vancouver, Canada) for 10 minutes at RT. To deplete lineage-positive cells, the 
supernatant containing unbound lineage-negative cells was poured into a fresh tube. 
The depletion step was repeated twice to increase lineage negative cell purity. 
 
Cryosectioning tissues 
Whole C57BL/6JARC adult spleen (7-months old) was immersed in a 10x10x5mm 
biopsy style Tissue-Tek Cryomold (Sakura Finetek, Tokyo, Japan) containing 
Tissue-Tek O.C.T (Sakura Finetek, Tokyo, Japan). Spleen tissue was placed into a 
foil vessel and frozen above liquid nitrogen. A CM1900 Leica cryostat (Leica 
Microsystems, Wetzlar, Germany) was set at approximately -14°C and sections 
were cut to 7µm thickness before applied to Sodalime white glass (UberFrost) Printer 





Tissue section fixation and staining 
Spleen sections were fixed in acetone (Sigma-Aldrich, St. Louis, MO, USA) for 5 
minutes at RT. The section slides were then washed three times in PBS for 3 minutes 
at RT. The underside of the slide was completely dried using a Kimwipe (Kimberly-
Clark, Irving, TX, USA). Each tissue section was first blocked with 25µL of Fc block 
(CD16/32) solution (see Table 2.4 for section staining concentrations) and incubated 
at room temperature for 30-minutes inside an incubation chamber (Cosmo Bio, 
Tokyo, Japan) to protect from light and moisture loss. Slides were drained of excess 
FcBl before 25µL of primary antibody solution was applied and incubated for 1-hour 
at RT. Table 2.4 lists staining concentrations used for primary antibodies.  All tissue 
section slides were then washed three times in PBS for 3-minutes at RT. The 
underside of the slides was dried and a coverslip mounted using Mowiol 4-88 
mounting medium (Sigma-Aldrich, St. Louis, MO, USA). Sections were visualized 
after 1-hour using a Nikon Live Cell Ti2 Microscope (details). All captured images 
were processed using ImageJ; FIJI v2.0.0 open source software (Laboratory for 
Optical and Computational Instrumentation; Maddison, MI, USA). 
 
Flow cytometry 
To analyse or isolate cells, flow cytometry was used in conjunction with a 
combination of primary antibodies and secondary reagents. Table 2.2 lists HSC 
staining antibodies, Table 2.3 lists antibodies used for homing and lineage 
characterization and Table 2.4 lists antibodies used for lineage reconstitution 
studies. Antibody cocktails were prepared by diluting primary antibodies 1:100 into 
FACS buffer, and secondary reagents prepared as a 1:400 dilution. Cell staining was 
performed in a 96-well tissue culture U-bottom plate (Sigma Aldrich, St. Louis, MO, 
USA) aliquoting a maximum of 2 x 106 cells per well. OneComp eBeads 
(eBioscience, San Diego, CA, USA) were added for all single colour controls except 
propidium iodide (PI). For antibody staining, 10µL of primary antibody cocktail was 




Cells were washed once with 150µL of FACS buffer and centrifuged again (5 
minutes, 200g at 4°C). The supernatant was discarded and the secondary reagent 
was added to wells for a further 10-minute incubation on ice, protected from light. 
Cells were washed again (150µL of FACS buffer), centrifuged and resuspended in 
150µL of FACS buffer. Cells were then transferred into a 5mL Falcon round bottom 
tube (StemCell Technologies, Vancouver, Canada) containing 2µl (10µg/mL) PI to 
discriminate cells as live (PI-) or dead (PI+). Cells were analysed or sorted using a 
FACSAria Fusion (Becton Dickinson Biosciences, San Jose, CA, USA). FlowJo 
v10.4.2 software (FlowJo, Ashland, OR, USA) was used for all post-acquisition 
analysis of FACS recorded experiments. 
 
Adoptive cell transfer via tail vein injection 
For intravenous injection via the tail vein, mice were gently placed underneath a heat 
lamp before placement in a cylindrical restraint device. The tail was swabbed with 
80% ethanol and 100µl cell solution injected into the tail vein using a 26G insulin 
syringe (BD, San Jose, CA, USA). The needle was removed and pressure applied 
at the insertion site to stem bleeding. Once the bleeding ceased, the animal was 
returned back to its cage. 
 
Intrasplenic injection 
Mice were sacrificed via cervical dislocation. An incision was introduced 
approximately 1.5cm in length above the spleen along the transverse plane on the 
left oblique abdomen. The skin was separated from the peritoneal wall using blunt 
scissors and the peritoneal wall above the spleen was incised. The spleen was either 
exteriorized with gentle pressure or excised completely from the body prior to 
injection. A 1:8 dilution of trypan blue (Sigma-Aldrich, St. Louis, MO, USA) in 
phosphate buffer solution (PBS) (Thermo Fisher, Waltham, MA, USA) was used at 
volumes of either 50µL, 25µL or 20µL in an Ultra-Fine 0.3mL 30G insulin syringe 




Injections administered to an excised spleen were held steady with Fine Point 
High Precision Forceps (Fisher Scientific, Hampton, NH, USA) while the needle was 
introduced along the coronal plane from the posterior extremity of the spleen. After 
slow fluid release, the needle was held in situ for approximately 30 seconds before 
the needle was slowly removed. The spleen was then observed by eye for 2 minutes 
after administration to assess progressive leakage with each volume. 
Injections into an exteriorized spleen, 10µL of standard formulation Corning® 
Matrigel® Matrix (Corning Inc., Corning, NY, USA) was first gently aspirated into an 
Ultra-Fine 0.3mL 30G insulin syringe (BD Bioscience, San Jose, CA, USA). Then in 
the same syringe, 20µL of trypan blue was carefully aspirated, avoiding bubbles and 
mixing of trypan blue/Matrigel layers. The exteriorized spleens were steadied using 
a Fine Point High Precision Forceps (Fisher Scientific, Hampton, NH, USA) as the 
needle was introduced along the coronal plane from the posterior extremity of the 
spleen. Once the volume had been slowly introduced, the needle was held in situ for 
approximately 30 seconds before slow needle removal. The spleen was then 
observed by eye for 2 minutes after administration to assess progressive leakage. 
Temperature of the spleen was not measured during the procedure. 
 
Dietary valine restriction 
Mice receiving cell transplantations were “pre-conditioned” using a dietary-based 
method for depleting HSC from bone marrow (Taya et al., 2016). Dietary-based 
preconditioning first involved a short fasting phase, followed by valine-restricted 
feeding, and finally valine reintroduction into the diet (Figure 2.1). During fasting, 
mice were restricted from feed for two days but given unrestricted access to water. 
During valine-restricted feeding, ‘L-amino acid rodent diet without L-valine’ 
(Research Diets Inc., New Brunswick, NJ, USA) was introduced for three weeks. 
Reintroduction of valine into the diet then commenced, coinciding with cell 
transplantation. Over this period, L-valine (Sigma Aldrich, St. Louis, MO, USA) was 




weeks at various concentrations (see Table 2.5) or through immediate introduction 
of a complete diet. 
 
Splenectomy 
Splenectomies were performed by anaesthetizing mice using a Darvall Stinger 
Streamline Isoflurane vaporizer (Darvall Vet; Gladesville, NSW, Australia) set at 5% 
for induction, and 3% for abdominal surgery. Analgesic (Buprenorphine, Temgesic, 
NSW, Australia) was administered via subcutaneous injection at 0.02mg/kg. To 
access the spleen, the abdomen was shaved and swabbed with 80% ethanol. An 
incision was made approximately 1.5cm in length above the spleen along the 
transverse plane on the left oblique abdomen. The skin was separated from the 
peritoneal wall using blunt scissors and the peritoneal wall above the spleen was 
incised. Using gentle application of pressure to exteriorize the spleen, the major 
arteries located under the spleen were ligated with a 26mm 1/2c taper suture needle 
and Ethicon Vicryl 5/0 suture thread (Ethicon Inc., Somerville, NJ, USA) before 
spleen was removed. To close the surgical site, the peritoneal cavity was sutured 
using 26mm 1/2c taper suture needle and Ethicon Vicryl 5/0 suture thread (Ethicon 
Inc., Somerville, NJ, USA) and the skin closed using an Autoclip device (BD, San 
Jose, CA, USA), affixing two wound clips (BD, San Jose, CA, USA) to close the 
incision site. Mice were monitored daily for signs of distress or discomfort. Non-
surgery control mice were housed in the same holding conditions over the same 
period. Splenectomised C57BL/6J mice used for aged analysis were maintained for 
9 - 18 months.  
 
Preparation of ex-breeder mice 
Female C57BL/6J mice splenectomised at the age of 4 weeks were bred for six 
cycles of litter production and held until nine months of age. Normal female 
C57BL/6J mice (aged 4 weeks) were simultaneously bred for six cycles as age-






This study ensures biological triplicates were performed as a minimum for each 
experiment, aiming for reproducibility of all data collected. Statistical analysis and 
graphics were conducted using GraphPad Prism version 7 (GraphPad Software, San 
Diego, CA, USA). For statistical analysis, a student’s t-test was used to compare 2 
normally distributed data sets. For non-parametric data analysis, a Wilcoxon test 
was used. A One-way ANOVA was used when 3 or more groups of parametric data 
were compared, with Tukey multiple-comparison post-hoc test  or Dunnett’s multiple 
comparison test to compare multiple data groups against a control group. Non-
parametric data was analysed using the Kruskal-Wallis multiple comparison test with 










1. Biolegend (San Diego, CA, USA) 
2. Miltenyi Biotec (Bergisch Gladbach, Germany) 
 
  
Specificity Clone Isotype Conjugate [Stock] 
(mg/mL) 
Source¤ 





Rat IgG2a, k Biotin 0.5 1 
CD48 HM48-1 Armenian 
Hamster IgG 
Biotin 0.5 1 
CD11c N418 Armenian 
Hamster IgG 
Biotin 0.5 1 
CD16/CD32 
(FcBl) 
93 Rat IgG2a, l Purified 0.5 1 




Table 2.2  Primary and secondary reagents used for HSC staining 
 
¤ Source: 
1. Biolegend (San Diego, CA, USA)  
2. eBioscience (San Diego, CA, USA) 
a eFluor660 (APC), allophycocyanin; APC-eFluor780 (APC-Cy7), 
allophycocyanin-Cy7; BV421, Brilliant Violet 421; FITC, fluorescein 
isothiocyanate; PE, phycoerythrin; PE-Cy7, phycoerythrin-Cy7 
 
  





2B8 Rat IgG2b, k FITC 0.5 3 
Ly-6A/E 
(Sca-1) 
D7 Rat IgG2a, k BV421 0.2 1 
CD150 mSHAD150 Rat IgG2b PE-Cy7 0.2 3 
CD34 RAM34 Rat IgG2a, k eFluor 660 0.2 3 
CD201 
(EPCR) 
eBio1560 Rat IgG2b, k PE 0.2 3 
Secondary reagent   












1. Biolegend (San Diego, CA, USA) 
2. eBioscience (San Diego, CA, USA) 
 




Specificity Clone Isotype Conjugatea [Stock] 
(mg/mL) 
Source¤ 
CD19 eBio1D3 Rat IgG2a, k PE-Cy7 0.2 2 
CD45R/ 
B220 
RA3-6B2 Rat, IgG2a, k PE 0.2 2 
CD5 53-7.3 Rat IgG2a, k BV510 0.2 1 
CD11c N418 Armenian 
Hamster IgG 
APC 0.2 2 
CD11b M1/70 Rat IgG2b, k PE-Cy7 0.2 1 
CD45.1 A20 Mouse IgG2a, k Pacific Blue 0.5 1 
CD45.2 104 Mouse IgG2a, k Biotin 0.5 1 
Secondary reagent   










1. eBioscience (San Diego, CA, USA) 
2. Biolegend (San Diego, CA, USA) 
3. Santa Cruz Biotechnology (Dallas, TX, USA) 
a AF488, Alex Fluor 488; PE, phycoerythrin 
  





93 Rat IgG2a, l Purified 0.5 2 
CD105 MJ7/18 Rat IgG2a, k PE 0.2 1 






Figure 2.1  Timeline for dietary valine restriction and donor cell 
transplantation 
Phase 1: The red zone indicates the 2 days during which mice are fasted before a 
3-week valine-deficient diet (Phase 2; light green zone). The dark green zone 
indicates the time of reintroduction of valine coincident with donor cell transplantation 















Table 2.5 Valine concentration in water during reintroduction diet 
Treatment group Week 1 (g/L) Week 2 (g/L) 
1 0 0 
2 0.1 1 
3 1 Complete diet 
4 Complete diet Complete diet 
Valine concentration in drinking water for various treatment groups. 
 
 
Table 2.6 Timepoints and conditions used for transplantation studies 
Analysis 
Timepoint 
Analysis Adoptive transfer: 
Cell type and 
number 
Double-staining 
18 hours Homing 2x106 whole spleen 
WBC 
DiR+CD45.2+ 
48 hours Homing 2x106 whole spleen 
WBC 
DiR+CD45.2+ 
1 month Short-term reconstitution 1x106cells lineage 
depleted BM 
CD45.1-CD45.2+ 
8 months Long-term reconstitution 1x106cells lineage 
depleted BM 
CD45.1-CD45.2+ 
Timeframes for homing and lineage reconstitution studies in valine-restriction 




















The spleen is an organ that filters blood. It also supports hematopoiesis and 
contributes to blood cell production. While spleen has been extensively investigated 
during stress or inflammatory events that trigger extramedullary hematopoiesis 
(McKim et al., 2018; Robbins et al., 2012; Tian et al., 2016; Wu et al., 2018), the 
contribution of spleen to hematopoiesis under steady-state conditions remains 
poorly understood. This is largely due to a lack of experimental methodologies that 
facilitate maintenance of steady-state conditions, and can discriminate between 
bone marrow and spleen-derived hematopoiesis.  
 
Irradiation and cytotoxic chemotherapy have been standard clinical practices for 
patient conditioning prior to HSC transplantation (Schofield, 1978). Niche 
preconditioning and HSC transplantation is also considered the gold standard 
method for studying hematopoiesis in animal models. However, such treatments 
severely damage the HSC microenvironment, potentially distorting the typical 
process of homing and differentiation (Chatterjee, Mills, Katz, McGarrigle, & 
Goldstone, 1994; Lapidot, Dar, & Kollet, 2005; Mohty & Apperley, 2010; Socie et al., 
2003; Tichelli et al., 2009). This includes changes in the level of secreted 
chemokines which can impact stem cell migration and repopulation potential 
(Lapidot et al., 2005). Therefore, alternate conditioning approaches are required to 
study hematopoiesis in the spleen under steady-state conditions. 
 
Many studies have focused on developing alternate approaches to HSC ablation in 
order to avoid the need for irradiation (Bueno, Montes, de la Cueva, Gutierrez-
Aranda, & Menendez, 2010; Czechowicz, Kraft, Weissman, & Bhattacharya, 2007; 
Palchaudhuri et al., 2016; Taya et al., 2016). Antibody-mediated methods involve 
the administration of ACK2, an antibody which is a cKit antagonist antibody. It 
depletes HSC through inhibition of cKit signaling rather than by bone marrow 




successful HSC engraftment in mice has not been achieved through antibody-
mediated approaches without combined low-dose irradiation (Xue et al., 2010). More 
recently, coupling ACK2 with CD47 antagonists was found to reduce the need for 
irradiation by initiating a macrophage-mediated phagocytic response (Chhabra et 
al., 2016). It is not yet known whether this method will contraindicate patient infection 
risk (Chhabra et al., 2016). Hematopoietic preconditioning through internalization of 
immunotoxins, produces excellent niche clearance and efficient chimerism in normal 
mice (Palchaudhuri et al., 2016). The immunotoxin used is specific for hematopoietic 
cells and utilizes the cell surface CD45 molecule on all blood forming progenitor and 
stem cells (Palchaudhuri et al., 2016). It is conjugated with saporin (SAP) 
(Palchaudhuri et al., 2016), a catalytic N-glycosidase ribosome-inactivating protein 
that inhibits protein synthesis (Bergamaschi et al., 1996). Exposure to SAP induces 
cell apoptosis and when coupled to a cell-specific antibody, such as CD45, allows 
highly targeted cell killing. This targeted killing  occurs independently of cell cycle 
status and gives prompt immunological recovery unlike total body irradiation 
(Rodriguez, Lim, Bartkowski, & Simons, 1998; Weidle et al., 2014). However, 
immunotoxin-mediated therapies are still in under development. Further 
investigation will be required to evaluate the risks associated with immunogenicity 
and the toxicity of immunotoxins, induced by either adaptive resistance mechanisms 
(Axelrod et al., 2013) or extensive cytokine-release (Jeyarajah & Thistlethwaite, 
1993).  
 
The extent to which hematopoiesis following preconditioning and transplantation is 
reflective of true physiological proliferation and differentiation remains unclear. Novel 
technical approaches to HSC tracking allow clonal dynamics to be monitored over 
time using transposon-based genetic tags (Gerrits et al., 2010) (Lu, Czechowicz, 
Seita, Jiang, & Weissman, 2019). The development of genetically modified 
immunodeficient mice engrafted with functional human immune systems now 
enables the human immune system to be studied on a small scale without putting 




shortcomings. For example, the development of graft-versus-host disease is 
inescapable in any transplantation model (King et al., 2009; Laing, Griffey, Moreno, 
& Stoddart, 2015), and the murine cytokine system is not competent at initiating 
human cell signaling cascades (Shultz, Brehm, Garcia-Martinez, & Greiner, 2012). 
The development of humanized mice deficient in murine MHC and/or CD47 may 
protect against graft-versus-host disease making them a unique and valuable model 
for long-term transplantation analysis (Lavender et al., 2013). 
 
Nutrition-based methods to condition mice have been assessed in order to 
circumvent the need for irradiation. One preconditioning approach previously 
reported by Taya et al. (2016) involves restricting the dietary intake of the essential 
amino acid valine to deplete HSC and progenitors from the bone marrow niche. The 
mechanism of action behind HSC-dependent valine sensitivity is not yet understood, 
although a recent report suggests that a valine deficient diet restricts HSC 
maintenance within the niche (Wilkinson, Morita, Nakauchi, & Yamazaki, 2018). One 
limitation of this method for HSC depletion is neurotoxicity in rats fed a diet deficient 
in valine, although symptoms can be quickly reversed upon reintroduction of valine 
into the diet (Cusick, Koehler, Ferrier, & Haskell, 1978; Taya et al., 2016). Since this 
study was initiated, a new dietary-based conditioning method has been published 
which shows that a lack of valine in the diet is not the primary cause of neurotoxicity 
in rats (Cusick et al., 1978) or of diminished HSC expansion in mice (Wilkinson et 
al., 2018). Instead it was found that an imbalance in the presence of the branched 
chain amino acids leucine and isoleucine was to blame (Wilkinson et al., 2018). This 
study suggested that depletion of all three branched chain amino acids may be a 
safer alternative for bone marrow conditioning (Wilkinson et al., 2018). 
 
A dietary-based pre-conditioning approach was investigated here as a cost-effective 
method to study steady-state hematopoiesis in preference to other procedures using 
antibody-mediated or hematopoietic-cell-specific immunotoxin-based approaches, 




humanized mouse models, dietary-based pre-conditioning allowed the use of mice 
on a common C57BL/6 background, and congenic variants for distinguishing donor 
cells from host. This study uses the dietary-depletion of valine in order to investigate 
steady-state spleen HSC lineage reconstitution. 
 
Migration of HSC through blood to various organs, and vice versa, requires active 
navigation mediated by functional cell adhesion molecules and chemokine 
stimulatory signals, a process called homing (Lapidot et al., 2005). Homing is a 
crucial process intrinsic to HSC. It is apparent from the first moments of ontogeny, 
seeding fetal bone marrow hematopoiesis, physiological roles in adult bone marrow 
homeostasis, through to the first essential step of therapeutic stem cell 
transplantation engraftment. Until recently, bone marrow was thought to be the 
primary site of HSC engraftment following HSC transplantation. It is now understood 
that spleen plays a crucial role in hematopoiesis and is one of the first sites visited 
by migrating transplanted HSC (Cao et al., 2004; Szilvassy, Bass, Van Zant, & 
Grimes, 1999).  
 
Spleen-specific hematopoiesis in the steady-state is challenging to study and 
therefore is fairly unexplored. One limitation of early reconstitution studies is the 
analysis of transplanted HSC weeks or even months after transplantation, while 
critical homing events occur within the first hours to days posttransplant (Cao et al., 
2004). Studies using bioluminescence imaging to track transplanted cell migration 
and homing report that approximately 37% of transferred HSC migrate to spleen, 
confirming spleen as the most frequent initial site of stem cell engraftment (Cao et 
al., 2004). Stem cells possess intrinsic programming that determines differentiation 
fate (Dykstra et al., 2007), however HSC within the spleen reportedly contribute to 
myelopoiesis, predominantly observed during stress-induced extramedullary 
hematopoiesis (Nakada et al., 2014), but also in the steady-state (Tan & O'Neill, 
2010). The power of the splenic niche to persuade stem cell fate decision may be 




spleen into primary recipients identified that HSC derived from spleen produced a 
larger proportion of myeloid than lymphoid cells than bone marrow derived HSC 
(Morita et al., 2011). Taken together with the understanding that HSC become 
progressively more myeloid-biased with age, it is important to consider whether 
frequent migration through the splenic niche is linked with myeloid-biased HSC 
accumulation. However, no previous studies have focused on this connection.  
 
Cellular expansion following transplant engraftment can be visualized in real time 
using live-cell imaging of fluorescence or bioluminescence. Furthermore, these 
technological applications have the potential to demonstrate homing and migratory 
patterns for individual cells in specific microenvironments. The study by Cao et al. 
(2004) reported that bioluminescence intensity gradually increased in HSC 
transplanted animals, which likely represented local proliferation and differentiation 
of donor-derived HSC and progeny. They also reported that bioluminescence foci 
could shift from the initial site of engraftment to other sites as bioluminescence 
intensity grew, indicating migration to other organs as proliferation occurred. 
Interestingly, Cao et al. (2004) identified a period of time when transplanted cells 
engraft and remain within the initial site of engraftment before foci begin to shift 
throughout the mouse, thus determining the time point after transplantation in which 
cells migrate. Provided lineage output analyses are conducted within the small 
window of time from initial engraftment, spleen-specific contribution to HSC lineage 
differentiation following transplantation can now be studied without the interference 
of bone marrow derived contributions.  
 
An important consideration for investigating spleen-specific hematopoiesis is 
separation of the confounding effects of hematopoiesis occurring in the bone marrow 
from hematopoiesis occurring in the spleen. Following transplantation, HSC migrate 
to multiple tissue niches in the body (Massberg et al., 2007). Intrasplenic injection 
has therefore been explored as a means of directly delivering HSC to the spleen, so 




of splenic hematopoietic output. However, even following intrasplenic injection, 
steady-state migration of HSC across various niches in the body (Cao et al., 2004) 
mitigates the initial localization of HSC to the spleen. This would compromise 
downstream hematopoietic reconstitution analysis typically performed 8-16 weeks 
after HSC transplantation. Therefore, to investigate tissue-specific hematopoiesis, 
we have analysed HSC differentiation in the spleen at early timepoints following 
either intravenous or intrasplenic transplantation. This is based on live cell tracing 
evidence of HSC homing, proliferation and migratory patterns specific to the spleen 
and bone marrow from a live cell tracing study (Cao et al., 2004). In mice 
transplanted with luciferase+ HSC intravenously, foci of engrafted HSC were found 
to remain localized in the spleen and bone marrow for 12 days after transplantation 
(Cao et al., 2004). This finding suggests that there is a specific 12-day window after 
HSC lodge in a hematopoietic niche while subsequent HSC proliferate and remain 
localized in the niche before migration occurs. Thus, in order to characterize spleen-
specific hematopoiesis, analysis must take place no more than 12 days after 
transplantation. 
 
Research surrounding proliferation and cell migratory patterns from newly engrafted 
HSC therefore offers a potential window to study HSC differentiation specific to the 
spleen microenvironment (Cao et al., 2004). In combination with a dietary-based 
method for conditioning HSC recipients, we have attempted to identify spleen-
endogenous HSC lineage differentiation and output under non-inflammatory 
conditions. This study is expected to bridge the gap between our understanding of 
extramedullary and steady-state spleen hematopoiesis in the spleen, and to 










3.2.1 Optimizing HSC clearance  
 
In order to investigate spleen-specific HSC differentiation under non-inflammatory 
conditions, we first attempted to 1) confirm the depletion of LT-HSC from niches 
including bone marrow following dietary valine restriction, and 2) identify the 
minimum amount of dietary valine needed to support HSC viability. These aims were 
concurrently assessed by varying concentrations of valine in the drinking water, 
while providing a valine-restricted diet over the entire depletion phase (Figure 3.1A). 
Analysis of percent LT-HSC in the bone marrow (Appendix A.1) following valine 
depletion revealed no significant difference between control animals given a 
complete diet, and animals given a valine-restricted diet (Figure 3.1B). Similarly, 
there was no significant difference found between either of the valine-restricted 
treatment groups compared with the complete diet positive control group, suggesting 
that valine-restriction did not deplete HSC. However, our finding of ~0.001% HSC 
remaining after 3-week valine restriction is consistent with previous depletion reports 
(Taya et al., 2016), and would suggest that this HSC frequency in bone marrow 
would be sufficient to permit donor cell engraftment. Instead, we consider that the 
HSC count for control mice given a complete diet was unexpectedly low. This was 
consistent with  LT-HSC frequency reported for control mice given a complete diet 
in the study by Taya et al. (2016), and also complete diet control mice in the 
refeeding analysis of this study (Figure 3.1C).  
 
It should be noted that previous data published in relation to valine-mediated HSC 
depletion pays particular attention only to HSC within the bone marrow niche. This 
study is therefore the first to analyse spleen tissue to assess whether HSC within the 
spleen niche were also simultaneously depleted as in the bone marrow (Figure 
3.1D). Initial results showed that HSC frequency amongst Lin- splenocytes was lower 
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Figure 3.1 The effects of valine depletion and reintroduction on bone 
marrow and spleen LT-HSC 
 
Optimization of valine-restriction to achieve hematopoietic stem cell (HSC) 
depletion. A) A schematic protocol for the depletion and reintroduction of valine into 
the diet. The fasting phase was initiated by a 2-day fast (red zone). Valine restriction 
was then commenced by introduction of a valine-deficient diet (light green pellet) for 
3 weeks (light green zone). Cell transplantation occurs following valine-restriction 
(black arrow), after which complete diet was returned (dark green pellets) as the 
valine refeeding phase (2 weeks; dark green zone). B) To determine the minimum 
valine concentration required to support HSC in the bone marrow niche, varying 
concentrations of valine were supplemented in the drinking water during the valine 
restriction phase. Lineage depleted (Lin-) bone marrow of 11-week-old C57BL/6J 
mice was analysed by flow cytometry to calculate LT-HSC frequency (frequency data 
not shown). LT-HSC have a L-S+K+CD150+CD48-CD34-EPCR+ phenotype. Data 
represent the meanSEM of 3 independent experiments (1 mouse/experiment), 
except for CD (complete diet; n=4). C) Varying concentrations of valine were 
reintroduced in weekly steps during the refeeding phase followed by analysis of bone 
marrow in 9-week-old mice. Data represent the meanSEM of 3 independent 
experiments (1 mouse/experiment): -Val (wk1)/-Val (wk2),0.1g/L (wk1)/ 1g/L (wk2), 
1g/L (wk1)/ CD (wk2) and CD (wk1)/ CD (wk2) (frequency data not shown). 
Statistical analysis was performed using a one-way ANOVA with Dunnett’s multiple 
comparisons test. *P<0.05. † Indicates that an animal died. D) Two independent 
experiments were carried out to analyse LT-HSC in the spleen of 8-week-old 
C57BL/6J mice given no valine compared with a complete diet (EXP1, EXP2) 





Based on these observations, we were satisfied that valine restriction led to depletion 
of HSC from the body. 
 
Next, we optimized the valine reintroduction protocol to determine the safest method 
to support hematopoietic engraftment. To avoid metabolic shock, valine was 
previously added to the drinking water incrementally at 0.12g/L of valine in the first 
week, and 1.2g/L in the second week (Taya et al., 2016). This method reduces 
mortality normally associated with immediate resumption of a complete diet. To 
determine the minimum dose of valine which supports HSC during the refeeding 
phase, we analysed bone marrow HSC frequency following the reintroduction of four 
varying concentrations of valine (Figure 3.1C). We confirmed a significant increase 
in HSC in mice fed a complete diet immediately after the valine depletion phase 
(0.006520.00147%SEM) compared with mice that were maintained on a valine 
restricted diet during the entire reintroduction phase (0.000040.00004%SEM).  
 
The percentage of LT-HSC in bone marrow gradually increased as the concentration 
of valine increased during refeeding. The 0.1g/L (wk1) group increased 20 times that 
of the ‘no valine’ refed group, while the least affected group was 1g/L (wk1) which 
increased 1.25 times the 0.1g/L (wk1) group, and lastly, the complete diet refed 
group increased by 6 times that of 1g/L (wk1) group. Amongst these groups, we 
determined that the minimum supporting dose of valine was 0.1g/L in the first week 
and 1g/L in the second week. Interestingly, we demonstrated the safety of valine 
reintroduction for 7 out of 7 mice surviving after immediate complete diet 
reintroduction. Therefore, based on HSC capacity for valine tolerance and 
demonstration of safety, we elected to reintroduce valine via resumption of a 
complete diet to support HSC transplantation.  
 





To confirm that valine restriction sufficiently preconditions the host HSC 
microenvironment while allowing donor cell homing, we tested the homing capacity 
of adoptively transferred hematopoietic cells using different transplant delivery 
routes. Homing is the first step following cell transplantation, with homing events 
measured in hours and typically lasting no longer than 1-2 days (Cao et al., 2004; 
Lapidot et al., 2005). We specifically wanted to confirm that any transplanted cells 
could home to the spleen, as the hematopoietic site of interest. We explored 
methods of improving the spleen-homing frequency by directly transferring donor 
cells into the spleen, instead of through intravenous administration. Considering that 
approximately 37% of intravenously transplanted cells lodge in spleen (Cao et al., 
2004), we hypothesized that transplanting cells directly into spleen would increase 
localization efficiency, and therefore increase the ability to detect HSC differentiation 
endogenous to spleen.  
 
In preparation for intrasplenic injection, we measured the maximum volume of fluid 
that could be injected into spleen (Figure 3.2A & B). Spleens excised from animals 
were imaged before intrasplenic injection of 50µL or 20µL volumes, and after 
delivery while the needle was still in situ, and then immediately after the needle was 
removed. We identified progressive leakage of trypan blue over 3-minutes using 
either 50µL or 20µL volumes, prompting further investigation into blocking the site of 
injection following fluid delivery.  
 
To reduce fluid escape from the injection site, we tested the introduction of a small 
Matrigel aliquot following adoptive cell transfer. Matrigel is an extracellular matrix-
based hydrogel that is liquid at cold temperatures and solid at body temperature.  To 
achieve a plug following intrasplenic injection, ice-cold Matrigel was first aspirated 
into a syringe followed by trypan blue dye to create a layered effect (Figure 3.2C). 
Injection of trypan blue only and trypan blue/Matrigel was directly compared showing 
a reduction in leakage when Matrigel was co-administered (Figure 3.2D). However, 




















































Figure 3.2 Investigating the viability of intrasplenic adoptive cell transfer 
 
Freshly harvested spleens from C57BL/6J or BALB/c mice were used to test the 
volumetric capacity of fluid injected directly into spleen, and to assess tissue damage 
associated with the injection. A) Schematic protocol for testing various injected 
volumes of trypan blue (TB) into a spleen to identify fluid retention and leakage. TB 
was drawn (20µL or 50µL) into an 30G ultrafine syringe and inserted into an excised 
spleen. B) Images of spleen (i) prior to injection, (ii) with needle in situ, then 
progressive leakage (imaged 3-minutes post-needle removal) from (iii) 50µL and (iv) 
20µL trials. C) Schematic protocol for testing whether progressive leakage could be 
reduced by using Matrigel (MG; indicated in pink) in layered effect, alongside normal 
TB control (indicated in blue), delivering MG into the spleen last. The site of injection 
was clamped with forceps. Intrasplenic injections were conducted in the exteriorized, 
but still attached spleen from the sacrificed host. D) Images of injections (i) using 
20µL TB only and 20µL TB and 10µL Matrigel. Images also show the needle 
removed while clamping is maintained (ii), and progressive leakage once the clamp 
is removed (3-minutes post-clamp removal) (iii). E) Spleen tissue following 
intrasplenic injection was frozen and cryo-sectioned for analysis by 
immunofluorescence staining. Sections (7µm) were stained with CD105 (MJ7/18; 
PE) (magenta) and ER-TR7 (SC-73355; AF488) (green). Yellow dotted line indicates 
path of injection. White arrow indicates trabecular damage, yellow arrow indicates 
endothelial cell lining of sinusoidal vasculature and white lines indicates points where 





To determine whether any tissue damage occurred following intrasplenic injection, 
spleen was sectioned and stained for expression of an endothelial marker (CD105) 
and fibroblastic marker (ER-TR7) (Figure 3.2E). A needle insertion path measuring 
26µm (15.5µm SD) in diameter was identified over two 7µm slides (Appendix A.2). 
In summary, due to technical difficulties and local tissue damage associated with 
intrasplenic injections, we used intravenous tail vein injections in order to examine 
spleen-specific hematopoiesis and to maximize steady-state conditions. 
 
3.2.3 Homing of transplanted cells following valine depletion as a pre-conditioning 
treatment 
 
To confirm that intravenously administered cells were capable of homing to the 
spleen, we transferred 2x106 C57BL/6 (CD45.2) spleen leukocytes into valine-
restricted B6.SJL (CD45.1) congenic hosts. To increase the specificity of donor 
(CD45.2) cell detection, a near-infrared lipophilic carbocyanine dye 1,1’-dioctadecyl-
3,3,3’,3’-tetramethylindotricarbocyanine iodide (DIR) was used to stain donor cell 
membranes prior to transplantation (Carlson et al., 2013). CD45.2+DIR+ cells were 
observed in all tissue samples analysed at 48-hours but not at 18-hours post-
transplantation (Figure 3.3). Amongst the tissues analysed, the majority of 
transplanted cells were found in spleen and peripheral blood (0.13%). Percent donor 
cells in the bone marrow (0.020%) was below the detection threshold of 0.1%. 
However, DIR cell membrane dye offered a robust double-positive stain that certified 
that any cell detection above 0% was donor-derived. This was confirmed using 
B6.SJL controls on which CD45.2+ DIR+ gates were set (Appendix A.3). Additional 
myeloid and lymphoid antibody staining found that most donor cells were B220+ B 
cells. Spleen and peripheral blood harbored a small percentage of F4/80-
CD11b+CD11c+ myeloid cells, with 4.6% myeloid cells detected in spleen and 11.1% 
detected in peripheral blood. Furthermore, 37.5% of donor cells detected in 
peripheral blood and 10.2% in spleen could not be classified as either myeloid, 
























































































































































































































































































































Figure 3.3 General homing capacity of cells transplanted into valine-
depleted recipients 
 
Donor spleen leukocytes (2x106) were isolated from C57BL/6 (CD45.2+) mice, 
stained with the lipophilic carbocyanine dye 1,1’-dioctadecyl-3,3,3’,3’-
tetramethylindotricarbocyanine iodide (DIR), and transplanted into valine-depleted 
B6.SJL (CD45.1+) host mice. At 18- and 48-hours post-transplantation, bone marrow 
(BM), spleen (SPL) and peripheral blood (PB) were collected and prepared for 
staining with antibodies to CD45.2 (104; Pacific Blue), B220 (RA3-6B2; AF647), CD5 
(53-7.3; BV510), F4/80 (BM8; PE), CD11b (M1/70; PE-Cy7), CD11c (N418; biotin) 
and streptavidin (BB515). Multi-colour FACS analysis was used to detect donor-
derived DIR+CD45.2+ cells. Dot plots showing DIR and CD45.2 expression display 
a standardized number of events (5578). DIR+CD45.2+ cells were further assessed 
for myeloid cells based on CD11c (N418; biotin & streptavidin; BB515), CD11b 
(M1/70; PE-Cy7) and F4/80 (Bm8; PE) expression. B and T cells were assessed 
through B220 (RA3-6B2; AF647) and CD5 (53-7.3; BV510) expression, respectively. 
Control B6.SJL (CD45.2-DIR-) mice were used to set (A) CD45.2 and DIR gates, and 
F4/80 fluorescence minus one controls (FMOC) were used to set (B) F4/80 (BM8; 
PE) gates (data shown in Appendix A.3). Numbers in gates represent percent cells 
amongst the parent population. The subset of interest is identified as DIR+CD45.2+ 




3.2.4 Lineage reconstitution potential from a valine depleted niche 
 
To initially determine the hematopoietic reconstitution potential of mice conditioned 
through valine restriction, 1x106 lineage-depleted CD45.2+ bone marrow cells from 
C57BL/6 mice were transplanted into valine depleted B6.SJL (CD45.1) recipients to 
perform a long-term reconstitution analysis. After 8 months, mice were considered 
positive for engraftment when hematopoietic (CD45.1+) chimerism was greater than 
0.1% (Camargo, Chambers, Drew, McNagny, & Goodell, 2006). This represents a 
threshold which accounts for background staining (<0.0072%) observed in CD45.2 
negative control mice (Appendix A.5). Here, we observed no donor engraftment in 
either bone marrow or spleen following long-term reconstitution. Despite 
transplanting a calculated 2-fold higher number of LSK cells (see Appendix A.6 for 
LSK frequency of lineage- bone marrow) than comparable studies (Taya et al. 
(2016), bone marrow donor chimerism for our study was 0.024%, lower than an 
expected ~15% chimerism. This finding suggests that pre-conditioning hosts using 
valine restriction requires further investigation to determine whether the lack of valine 
restricts engraftment efficacy of the host niche, and whether engraftment can be 
improved if valine is returned to the diet prior to HSC transplantation. 
 
To address whether host valine-deficiency at the time of transplantation was the 
cause of poor lineage reconstitution, we returned valine to the diet one or two days 
prior to transplantation of 1x106 lineage-depleted bone marrow cells (Figure 3.4B). 
After 4 weeks for analysis of short-term lineage reconstitution, 1-day of valine 
prefeeding prior to transplant resulted in 1 out of 2 mice being positive for donor cell 















































































































































































































































Figure 3.4 Optimizing donor hematopoietic reconstitution in valine-depleted 
hosts 
1x106 lineage-depleted BM cells were prepared and transplanted into valine-depleted 
hosts as described in Figure 3.1A. A) At 8 months following transplantation, bone marrow 
(BM) and spleen (SPL) tissue was harvested and analysed by flow cytometry for long-
term donor chimerism. Antibodies specific for CD45.1 (A20; Pacific Blue) and CD45.2 
(104; biotin & streptavidin; APC-eFluor 780) were used to delineate donor cell populations 
(CD45.2+CD45.1-). Recipients were considered positive for engraftment when donor 
chimerism was >0.1%. C57BL/6ARC (CD45.2) and B6.SJL (CD45.1) mice were prepared 
separately as gating controls. B) Schematic protocol for re-introducing dietary valine 
(complete diet) -1 and -2 days prior to cell transplantation (Day 0). C) Valine-depleted 
mice were refed with complete diet at either 1 day (n=2) or 2 days (n=3) prior to 
transplantation with 1x106 CD45.2 lineage depleted bone marrow cells. Donor chimerism 
in the bone marrow was assessed at 4-weeks post transplantation. Donor chimerism is 





The group given two-day valine pre-feeding displayed positive engraftment with an 
average donor chimerism level of 0.41% (0.1% SEM) from 3 mice. Lineage 
differentiation analysis revealed that the majority of donor-derived cells expressed B220 
(B cell marker) for both day -1 (88.1%5.8%SEM) and -2 groups (55.7%19%SEM), but 
no CD5+ T cells were identified (Appendix A.5). Myeloid expression was only successful 
in one technical experiment reporting 12.7% on day -1 and 50.9% (12%SEM) on day -2 
(Appendix A.5). Controlled lineage analysis, using C57BL/6 mice, found 67.5% 
(2.8%SEM) of cells were B cells, 25.8% (1.8%SEM) were T cells and 13.3% were 
myeloid cells (Appendix A.5). The distinction evident between the experimental and 
control findings is the absence of T cell expression in all mice transplanted for short-term 
reconstitution. This finding confirms greater lineage chimerism and engraftment results 
than this study has seen before, suggesting that valine pre-feeding is required for 
transplant engraftment. Pre-feeding valine 2 days before transplant administration yielded 







In this study, we adapted a novel preconditioning method, first reported by Taya et al. 
(2016), to investigate steady-state lineage differentiation of HSC in spleen. As this was a 
recently published model, we first attempted to optimize the technique for our purpose, 
with the end goal of transplanting HSC for analysis of spleen-specific differentiation. 
Overall, we achieved an optimized method for valine depletion, assessed transplantation 
delivery options, and optimized an adoptive cell transfer protocol for maximum 
engraftment. These findings now set a foundation for future HSC studies. 
 
We designed the first trials for valine-restricted preconditioning using the protocol from 
Taya et al. (2016). In this report, mice were fasted prior to diet introduction and maintained 
on a valine-deficient diet or complete diet for a maximum of 4 weeks, followed by valine 
reintroduction. No change was observed in the reduction of HSC frequency between 
week 3 and 4 of valine restriction (Taya et al., 2016). We therefore began our initial 
experiments with a 3-week depletion phase (Figure 3.1A).  
 
We did not detect a significant difference in LT-HSC number between the valine depleted 
negative control and the control group fed a complete diet. Since LT-HSC percentages in 
the bone marrow of valine depleted mice were within the range of previously published 
data (Taya et al., 2016), this indicated that control mice had a lower than expected LT-
HSC frequency. This was further supported by LT-HSC frequency in valine-restricted 
mice fed a complete diet (Figure 3.1C) which was higher and within the range of normal 
mice (Chen et al., 2008; Kiel et al., 2005; Oguro et al., 2013; Taya et al., 2016). We also 
analysed the spleen in addition to bone marrow since no previous study has investigated 
whether valine-restriction depletes LT-HSC from spleen (Figure 3.1D). We report that 
HSC in spleen appear to be virtually depleted in comparison with HSC in spleens from 
mice fed a complete diet. However, since these results are based on two independent 





The valine refeeding phase was initially approached with caution due to reports of 
metabolic shock in mice immediately refed valine after a period of depletion (Taya et al., 
2016). We tested different valine refeeding concentrations over the course of 2 weeks, 
increasing the valine concentration weekly. Contrary to the report by Taya et al. (2016), 
we found that no mice died after immediate reintroduction of a complete diet (Figure 
3.1C). It is not clear as to why our mice did not die from immediate reintroduction of 
complete diet since both studies used 8-12 week-old C57BL/6 mice and were fed a valine 
depleted diet purchased from the same company (Research Diet; New Brunswick, NJ, 
USA).  
 
Next, we compared intrasplenic adoptive cell delivery with traditional intravenous delivery 
method for cell homing towards the spleen.  The aim was to characterize the small LT-
HSC population localized in the spleen for their hematopoietic output. Since the LT-HSC 
population is much smaller than that in the bone marrow, we hypothesized that direct 
introduction of donor cells into the spleen would offer a greater chance for cells to engraft 
and proliferate in the spleen environment, creating a larger and more easily detectable 
output for characterization. Since intrasplenic injection is no longer a recommended route 
of administration as detailed by the most current global authority on the care of mice in 
laboratory research (Hirota & Shimizu, 2012), the technique was investigated before use 
in a transplantation experiment. We first tested intrasplenic injections on excised spleens 
of sacrificed mice (Figure 3.2A). Aliquots of 50µL and 20µL trypan blue were given to 
visualise the fluid retention and spillage from spleen (Figure 3.2B). Progressive leakage 
was noted for both volumes. This finding was at odds with other published protocols that 
use this method with much higher volumes (up to 200µL) and no apparent leakage (Miki, 
Takano, Garcia, & Grubbs, 2019).  
 
We questioned whether leakage was due to the lack of blood circulation in the sacrificed 
mouse, and whether fluid retention increased when the spleen remained attached to the 
host. We hypothesized that spleen attachment via its vasculature may support fluid 
displacement upon injection. We also tested whether layering a small aliquot of Matrigel 
in the syringe after cell aspiration would create a seal around the site of injection to 
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prevent spillage (Figure 3.2C). Matrigel changes from a liquid to solid state at body 
temperature, and so a clamp was used at the site of injection to give time for the Matrigel 
to solidify once introduced into the spleen. From trials with Matrigel, we noticed that the 
layering effect (Matrigel aspirated first, then cells) was not achievable without having 
some of the cells mixing with the Matrigel during the liquid state in the syringe. Even with 
the addition of a Matrigel ‘plug’, progressive leakage was still evident (Figure 3.2D).  
 
Finally, to confirm that intrasplenic injections were an effective method for cell transfer, 
we analysed spleen sections stained for fibroblastic and endothelial markers to identify 
architectural damage in the spleen microenvironment (Figure 3.2E). A clear path of 
destruction was evident in the injected spleen consistent with development of an 
inflammatory response (Chen et al., 2018), so compromising the steady-state condition 
(Appendix A.2). In conclusion, intrasplenic injection was not viable due to technical 
difficulties. Thus, only intravenous adoptive cell transfer was used for further 
transplantation experiments. 
 
Next, the homing capacity of intravenously delivered cells was analysed. We failed to see 
any homing to spleen, bone marrow and peripheral blood by 18-hours after delivery 
(Figure 3.3). This was surprising as previous reports showed that approximately 4% and 
5% of transplanted murine bone marrow cells could be found in the spleen and bone 
marrow at 18 hours after transplantation, respectively (Szilvassy et al., 1999). It is likely 
that donor cells home to non-hematopoietic organs like the lungs, rather than the bone 
marrow or spleen (Cui et al., 1999; Massberg et al., 2007; Szilvassy et al., 1999). We 
then identified donor cells at 48 hours after transplantation in the peripheral blood and 
spleen (Lanzkron, Collector, & Sharkis, 1999), but not in bone marrow. One hypothesis 
is that the  lack of donor cell detection in bone marrow is due to the homing selectivity of 
cells (Plett, Frankovitz, & Orschell, 2003; Szilvassy et al., 1999). Transplanted HSC or 
bone marrow-derived leukocytes migrate to the spleen for the first 3 hours 
posttransplantation and then  preferentially home towards the bone marrow (Szilvassy et 
al., 1999). However whole spleen leukocytes were transplanted and B cells were 




homing (Szilvassy et al., 1999) as an explanation for  the lack of donor cell detection in 
the bone marrow. For example, B cells are reported to selectively home towards spleen 
(Wols et al., 2010). Our findings were confirmed since HSC in spleen are rare (Tan & 
O'Neill, 2010), and approximately 50% of spleen leukocytes comprise B cells (Appendix 
A.4). Overall, donor spleen leukocytes are detectable at low levels in peripheral blood 
and spleen of valine depleted hosts at 48 hours posttransplantation, but bone marrow 
homing was not apparent.  
 
Long-term lineage reconstitution assays were also performed (Figure 3.4A) using 
lineage- bone marrow, however no donor chimerism was detected after 8 months. 
Explanations for the lack of donor chimerism are that, firstly, the cell dose given was too 
low, consistent with evidence that transplantations achieve different donor chimerism 
levels for different cell doses transplanted (Rao et al., 1997; Westerhuis, van Pel, Toes, 
Staal, & Fibbe, 2011). On the premise that LSK constitutes 0.5% of lineage depleted bone 
marrow (Challen et al., 2009), we injected 1x106 lineage- bone marrow cells, comprising  
~5000 LSK. From our own data we identified that the frequency of LSK cells within 
lineage- bone marrow is ~ 0.01% (Appendix A.6). This suggests that our transplants 
contained only 100 LSK as opposed to the predicted 5000 LSK. However, engraftment 
and long-term lineage reconstitution has been previously reported in mice transplanted 
with as few as 10 LSK (Camargo et al., 2006), suggesting that cell dose was not a limiting 
factor. The second potential reason could be the lack of valine at the time of 
transplantation, since valine is a vital amino acid necessary for proliferation and 
maintenance of HSC (Taya et al., 2016). A previous study reported donor chimerism of 
~15% (~10%SD), although this result was low and variable. We therefore reasoned that 
it would be necessary to address niche conditions and valine availability at the time of 
transplantation with a view of increasing the likelihood of engraftment.  
 
By transplanting 1x106 lineage depleted CD45.2+ bone marrow either 1- or 2-days 
following valine reintroduction into the diet (Figure 3.4C), donor chimerism was achieved 
at levels higher than previously observed (Figure 3.4A). The same number of lineage- 
bone marrow cells (1x106) was transplanted in both the long- and short-term lineage 
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reconstitution experiments, although only successful engraftment was achieved in short-
term analyses (>0.1%). We attribute this success to either increased valine availability or 
to the fact that the donor cells comprise short-term progenitors (Camargo et al., 2006). 
Low numbers of LT-HSC in the transplant (Benveniste, Cantin, Hyam, & Iscove, 2003), 
and low survival rate of transplanted cells on engraftment in hematopoietic organs versus 
non-hematopoietic organs (eg. lungs, etc.) (Cui et al., 1999), are also confounding factors 
that could reduce engraftment. This is especially prominent in unirradiated hosts. A 
limitation of our short-term refeeding analysis was the absence of a day-0 valine refed 
control. Donor cells should have been transplanted on the day that valine refeeding was 
commenced, alongside the 1- and 2-day refed groups in order to directly compare 
differential valine availability. We recommend that refeeding should recommence 2-days 
prior to transplant since only one out of two 1-day refed transplantations worked, and all 
2-day refed replicates were successful. Inefficient transplant delivery, and the likelihood 
that cells delivered failed to home to a hematopoietic organ, could account for the 
unsuccessful 1-day transplant (Benveniste et al., 2003; Cui et al., 1999).  
 
Based on results presented here, we conclude that spleen-specific lineage output 
characterization studies in the steady-state condition can be best achieved using the 
optimized valine-restriction preconditioning method and by allowing 2-days of valine 
reintroduction prior to transplantation. Cell-dose titration is necessary to enhance donor 
engraftment since valine-restriction preconditioning does not clear hematopoietic niches 
entirely. Further research is required to identify the appropriate cell dose prior to 
performing optimal transplantation assays. LT-HSC must be sorted and intravenously 
transplanted, such that cell differentiation in this period must originate from LT-HSC. One 
third of intravenously transplanted HSC engraft in the spleen, and based on single HSC 
transplantation studies, do not migrate from the initial site of engraftment for up to 12 days 
(Cao et al., 2004). Bulk as opposed to single cell LT-HSC transplantation and engraftment 
will increase the sensitivity of detecting small numbers of progeny cells at early 
timepoints. Spleen-specific analysis must take place between 12-17 days post-
transplantation, before proliferation and migration of engrafted cells occurs (Cao et al., 




differentiation of all mature hematopoietic cell types (Yamamoto et al., 2013), otherwise 
expansion within the first 12 days will not distinguish between short term or long term 
reconstitution without progenitor analysis.  Further analysis could investigate whether a 
ST-HSC or an MPP subtype would best suit the short-term reconstitution analysis, or 
whether progenitor characterization versus mature lineage characterization would best 





















Little is known about hematopoiesis in spleen under physiological conditions and whether 
this has any impact on overall changes in hematopoietic cell output associated with aging. 
Long-term (LT)-HSC are defined by a lineage-cKit+Sca-1+(LSK)CD48-CD150+CD34- 
phenotype, and the addition of EPCR (CD201) as a marker further delineates tissue-
resident stem cells (Balazs et al., 2006; Gur-Cohen et al., 2015). LT-HSC can also be 
functionally distinguished as balanced or myeloid-biased based on differential CD150 
expression. This classification of HSC is important because hematopoiesis from HSC 
over age is characterized by a gradual skewing of lineage output shifting from a balanced 
(1:4 to 1:2) myeloid and lymphoid output in young animals towards a myeloid-dominant 
(>1:2) output with aging (Beerman et al., 2010; Benz et al., 2012). This change over time 
is indicated by a change in relative proportion of CD150lo versus CD150hi HSC 
populations, representing balanced (CD150lo) and myeloid-biased (CD150hi) HSC 
respectively. Within the LSKCD34-Flt3- compartment, the proportion of the different 
subsets have been defined:17% CD150hi, 56% CD150lo and 26% CD150- HSC in young 
animals corresponding with balanced hematopoietic cell output (Beerman et al., 2010). 
In the same study, myeloid-biased hematopoiesis in old (24-month) mice was associated 
with 58% CD150hi, 34% CD150lo and 8% CD150- HSC distribution (Beerman et al., 2010). 
Thus, younger animals display a higher proportion of CD150lo balanced HSC, compared 
with older animals which express a higher proportion of CD150hi, or myeloid-biased LT-
HSC (Beerman et al., 2010).  
 
The question of whether intrinsic or extrinsic factors control HSC fate is an area of debate 
and investigation. One hypothesis is that age-associated myeloid-biased lineage skewing 
could be due to HSC mobilization into niche spaces outside of the bone marrow, for 
example spleen. Extramedullary hematopoiesis occurs mostly under stress conditions 
and leads to the migration of HSC from bone marrow towards spleen, where they 
contribute to hematopoiesis within sinusoidal niches (Inra et al., 2015; Wright et al., 2001). 
While hematopoiesis within spleen predominantly supports myelopoiesis (Inra et al., 
2015; Nakada et al., 2014; Tan & O'Neill, 2012), HSC isolated from the spleen and 
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adoptively transferred into irradiated hosts can demonstrate multi-lineage potential (Tan 
& O'Neill, 2010). Therefore, microenvironmental cues delivered specifically by the spleen 
could exert myelopoietic programming on otherwise multipotent HSC. 
 
One important issue, therefore, is the extent to which HSC might become “programmed” 
during mobilization into the spleen and then maintain a myeloid-biased differentiation 
pattern following migration back into the bone marrow. In one study (Morita et al., 2011), 
LSKCD34- HSC from either the bone marrow or spleen were transplanted into irradiated 
mice (Figure 4.1.1A). Bone marrow from primary recipients containing either donor BM-
derived or donor spleen-derived HSC was then transplanted into secondary recipients 
(Figure 4.1.1B). This study reported increased myeloid cell production in secondary 
recipients originally given spleen-derived donor HSC as a primary transplant (Figure 
4.1.1C). Spleen-derived HSC originally transplanted into the primary recipient must have 
first migrated into bone marrow, and then retained myeloid-biased programming upon 
secondary bone marrow transplantation (Figure 4.1.1). This finding offers evidence that 
the spleen microenvironment not only enforces local myelopoiesis, but may imprint this 
behavior even after HSCs have left the spleen. 
 
Figure 4.1.1 Long-term reconstitution by bone marrow or spleen LSKCD34- cells. Figure 
adapted from (Morita et al., 2011). A) Primary recipient transplant. B) Secondary recipient 
transplant. C) Average % chimerism and lineage analysis from secondary transplant 
recipients represented. 
 























It is therefore our hypothesis that through this mechanism, the spleen microenvironment 
contributes to the skewing HSC to give a myeloid-bias in the bone marrow with age. Under 
steady-state conditions, HSC are constantly migrating between niches in the body, 
evidenced by HSC found in the peripheral blood outside of stem cell niches (Wright et al., 
2001). If stem cells are constantly shuffling between hematopoietic niches in body, and if 
the spleen niche imprints migratory HSC with myeloid-biased programming, then over a 
lifetime, the movement of HSC between the spleen and bone marrow may result in the 
gradual accumulation of myeloid-biased HSC within the animal. 
 
One potential method to test whether the spleen contributes to the build-up of myeloid-
biased HSC over a lifetime is to push stem cell emigration towards the spleen at a higher 
rate, so replicating or exacerbating the characteristics of aging. Pregnancy, in particular, 
is known to induce extramedullary hematopoiesis in the spleen due to an increase in 
estrogen levels (Nakada et al., 2014). In this study, we propose a model for accelerating 
the effects of steady-state aging by increasing the rate of HSC mobilization and 
movement between bone marrow and spleen hematopoietic niches, through inducing 
pregnancy on multiple occasions. Here, large number of HSCs are expected to migrate 
into spleen and become imprinted with a myeloid bias before returning to bone marrow 
niches. Therefore, splenectomised exbreeder mice that have undergone multiple rounds 
of pregnancy would maintain a ‘younger’ HSC phenotype, in comparison with normal 
exbreeder mice which would exhibit a higher proportion of myeloid-biased HSC. 
 
In the previous chapter, we began to address the contribution of spleen to steady-state 
myeloid cell production. In this chapter, we aim to determine whether spleen contributes 
to an accumulation of myeloid-biased LT-HSC over age by directly comparing the 
frequencies of CD150hi HSC in normal young, normally aged and aged asplenic mice. 
Here we use pregnancy as a model of HSC aging. Comparisons have been made 
between age-matched normal exbreeder and asplenic exbreeder mice that have 
undergone multiple cycles of pregnancy to induce extramedullary hematopoiesis. These 
mice were tested to determine whether increased exposure to splenic niches drives the 





4.2.1 Determining CD150hi/lo/- expression amongst LT-HSC 
 
To assess whether the spleen plays a role in the rise of myeloid-biased CD150hi HSC 
with old age, we first verified that a CD150hi/lo/- gating strategy could be applied to LT-
HSC in order to distinguish myeloid-biased and balanced HSC, respectively. Myeloid-
biased LT-HSC have previously been identified using a lineage-cKit+Sca-1+CD150hiCD48-
CD34- phenotype. For this study, a gating strategy was adapted from both Beerman et al. 
(2010) and Benz et al. (2012) to distinguish tissue-endogenous EPCR+ HSC as CD150hi 
myeloid-biased LT-HSC, balanced LT-HSC as CD150lo, and lymphoid-biased ST-HSC as 
CD150- (Challen, Boles, Chambers, & Goodell, 2010; Morita et al., 2010) (Figure 4.2.1). 
 
Following several different experimental trials, a strategy which delineated differential 
CD150 expression amongst LT-HSC was established. Gating for no expression of CD150 
and CD34 was achieved using two separate fluorescence minus one controls (FMOC) for 
each antibody. To prepare LT-HSC for flow cytometric analysis, magnetic depletion of 
cells expressing mature lineage cell markers (CD11c, Gr-1, NK1.1, CD48) was performed 
with biotinylated antibodies.  The remaining lineage+ cells were identified by flow 
cytometry using APC-eFluor 780-conjugated streptavidin for exclusion during the gating 
process. Following the lineage- gate, cKit+ and Sca-1+ cells, otherwise known as the LSK 
subset, were subsequently selected to display CD150 and EPCR expression. Boundaries 
for EPCR+ gates as well as CD150lo gates were applied using an internal control 
population (Lin-cKit+Sca-1-). This control represents a myeloid progenitor (CMP or MEP) 
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Figure 4.2.1 Defining a gating strategy to consistently report differential CD150 
expression on LT-HSC. 
  
The gating strategy used to define LT-HSC and sub-populations of short-term (CD150-), 
long-term balanced (CD150lo) and myeloid-biased (CD150hi) HSC is shown. Plots are 
representative of a 5-month-old C57BL/6J female mouse. Red blood cell lysed bone 
marrow cells were magnetically depleted of mature cells using biotinylated CD48 (HM48-
1), NK1.1 (PK136), CD11c (N418), and Gr-1 (RB6-8C5) lineage marker antibodies. Cells 
were analysed by flow cytometry for the Lineage-cKit+Sca-1+(LSK) CD150+CD34-EPCR+ 
phenotype using antibodies specific for cKit (2B8; FITC), Sca-1 (D7; BV421), CD150 
(mSHAD150; PE-Cy7), CD34 (RAM34; eFluor 660) and CD201 (eBio1560; PE). 
Streptavidin (SA)-APC-eFluor 780 was used as a secondary reagent to detect any 
remaining undepleted lineage+ cells. Prior to flow cytometry, cells were stained with 
propidium iodine (PI-) to include only PI- viable cells in further analyses. The gating 
strategy identifies the criteria which define LT-HSC and CD150hi/lo/- subsets. Percent 
positive cells is indicated in each plot. Fluorescence minus one controls (FMOC) for CD34 
and CD150 were used to set gates to exclude CD150 and CD34 expression.  Final plots 




In order to accurately set the CD150lo gate, all plots were standardized to display the 
same number of events for internal controls (592). With a constant event number 
displayed, the upper boundary of the CD150lo gate was placed at the level of the highest 
recorded event, or gating 98% of events in cases where outliers were evident (events 
registering at intensity levels of ≥104). In this representative example, we show that the 
CD150hi, CD150lo and CD150- populations make up 27.5%, 52% and 20.6% of HSC, 
respectively.  
 
Aging studies that focus on myeloid-biased HSC proliferation typically rely on CD150 
expression changes in variably aged animals. In an alternative approach, the median 
fluorescence intensity (MFI) of CD150 staining can be investigated as a potentially more 
sensitive method of detecting shifts in CD150 expression amongst variably aged LT-HSC 
populations. A 5-month-old C57BL/6J female mouse was analysed for the CD150+ LT-
HSC population to establish a baseline reading for young animals (Figure 4.2.2). Since 
CD150- expression phenotypically defines ST-HSC, this population was excluded in order 
to allow assessment of only CD150+ LT-HSC. In the representative figure, the MFI for LT-
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Figure 4.2.2 Gating strategy to determine CD150 median fluorescence intensity on 
LT-HSC 
 
The gating strategy used to define HSC and sub-populations of short-term (CD150-), long-
term balanced (CD150lo) and myeloid-biased (CD150hi) HSC in Figure 4.1 was modified 
to identify the median fluorescence intensity (MFI) of CD150 expression. Plots are 
representative of lineage-depleted bone marrow cells isolated from a 5-month-old 
C57BL/6J mouse. Bone marrow cells were prepared as outlined in Figure 4.1. Live, 
singlet, lineage-cKit+Sca-1+ (LSK) EPCR+ cells were initially selected before all CD150+ 
cells were gated, indicated by the “LSK EPCR+ CD150+” MFI gate. Subsequently, CD34- 
gated cells were analysed for CD150 MFI. The MFI of the representative figure is 
identified as a grey dotted line on the final LSKCD34-EPCR+CD150+ plot. Final plots are 
illustrated as a ‘smoothed’ display with outlier’s present. Axis intensity values are arbitrary 





4.2.2 Assessing the spleen’s influence on LT-HSC populations in young and old mice 
 
Once CD150hi/lo/- expression levels could be established, the proportions of CD150hi to 
CD150lo to CD150- cells amongst ESLAM gated LT-HSC of young (2-5 months), old (18-
22 months) and old asplenic (18-22 months) mice were compared (Figure 4.2.3A). A 
significant increase in frequency of CD150hi HSC was found in young over old control 
groups. This was expected as previously reported (Beerman et al., 2010). However, there 
was no significant difference in the frequency of CD150lo HSC between young and old 
mice. We observed no statistical difference in the frequency of CD150hi, CD150lo or 
CD150- HSC populations between aged normal and aged asplenic mice. We also 
compared the CD150+ LT-HSC compartment (Figure 4.2.3B), but found no significant 
difference in CD150hi HSC frequency amongst total CD150+ cells between young, old or 
old asplenic groups. 
 
The MFI of CD150 expression was then calculated for the LSKCD34-CD48-EPCR+ LT-
HSC population for each animal group (Figure 4.2.3C). Consistent with previous 
research, CD150 MFI was lowest in young mice (1632.2  346.1). However, we did not 
detect any significant increase in CD150 MFI between young and old mice. Similarly, the 
CD150 MFI between old (3165.4  305.4) and old asplenic (3658777.8) mice was not 
significantly different. Taken together HSC frequency (Figure 4.2.3A & B), and MFI of 
CD150 (Figure 4.2.3C), all results confirm that between old and old asplenic animals, the 
absence of spleen does not appear to have an effect on the development of aged CD150hi 
HSC.  
 
Lastly, we analysed the frequency of bone marrow CD150+ LT-HSC (Figure 4.2.3D) and 
total bone marrow cellularity (Figure 4.2.3E) for each group. There was no statistical 
difference in CD150+ LT-HSC number between young and old control mouse groups, or 
between old and old asplenic groups (Figure 4.2.3D). Similarly, no difference was 
observed in bone marrow cellularity between any group (Figure 4.2.3E). These data 
suggest that the absence of a spleen did not change the normal physiological aging 







































































































































































































































































































































































































Figure 4.2.3 Analysis of HSC populations amongst young, old and old asplenic 
mice. 
 
Lineage depleted bone marrow cells were prepared as outlined in Figure 4.1 and stained 
with antibodies specific for cKit (2B8; FITC), Sca-1 (D7; BV421), CD150 (mSHAD150; 
PE-Cy7), CD34 (RAM34; eFluor 660) and CD201 (eBio1560; PE). Streptavidin (SA)-
APC-eFluor 780 was used as a secondary reagent to stain any remaining undepleted 
lineage+ cells. Prior to flow cytometry, cells were stained with propidium iodide (PI) to 
discern live viable cells (PI-) from apoptotic cells. A) Graph shows percent CD150hi, 
CD150lo and CD150- cells amongst LSKCD34-CD48-EPCR+ LT-HSC from young (2-5-
months-old) (n=7), old (18-22-months-old) (n=5) and old asplenic (18-22-months-old) 
(n=4) mice over seven independent experiments. B) Percent CD150hi LT-HSC amongst 
CD150+ LT-HSC from (A).  C) Median fluorescence intensity (MFI) of CD150 on LT-HSC 
from young (●; n=5), old (■; n=5), and old asplenic (▲; n=4) mice.  Data show the 
meanSEM of five independent experiments. D) CD150+ LT-HSC number calculated from 
percent of total CD150+, multiplied by total live lineage depleted bone marrow cells, 
collected from two femurs of the same mouse. E) Cellularity represents total live lineage-
depleted bone marrow cells, collected from two femurs of the same mouse. All error bars 
represent SEM. Data was analysed using either a parametric one-way ANOVA with 
Tukey multiple comparisons test (B, C, D & E) or a two-way mixed effect ANOVA with 
Tukey’s multiple comparisons test (A). Significant P values are indicated as (*) when 





interpreted with caution since differences between control young and old mice were also 
not detected (Figure 4.2.3B, C, D & E). 
 
 4.2.3 Assessing myeloid-biased CD150hi LT-HSC in asplenic and normal exbreeder mice 
 
Pregnancy is known to increase the migration of HSC from the bone marrow into spleen 
during extramedullary hematopoiesis (EMH) (Nakada et al., 2014). The exbreeder mice 
used in this experiment had undergone six cycles of pregnancy, and consequently 
repeated EMH events of BM HSC mobilization into the spleen. Therefore, we investigated 
whether the absence of a spleen would reduce the frequency of CD150hi HSC present in 
the bone marrow compared to non-splenectomised exbreeder counterparts. Such an 
outcome may suggest that the increase in myeloid-biased HSC with age is linked to the 
spleen HSC microenvironment.  
 
In order to test this, we analysed bone marrow HSC from normal exbreeder and asplenic 
exbreeder mice. The gating strategy from Figure 4.2.1 was applied to identify differential 
CD150 expression on LT-HSC in all experiments. We found no significant difference in 
proportion of CD150hi or CD150- HSC between normal and asplenic exbreeder. However, 
we did observe a small but significant (P=0.034) increase in the size of the CD150lo HSC 
population in asplenic exbreeder compared with normal exbreeder mice (49.5%3.3 and 
34.1%4.7%, respectively) (Figure 4.2.4A). Interestingly, the size of the CD150hi HSC 
population did not increase with the decrease in size of the CD150lo HSC population in 
normal exbreeder mice as might be expected. This could be due to large variation in 
CD150hi expression in normal exbreeder (53.9%8.3%) over asplenic exbreeder 
(36.6%2.8%) mice. Lastly, we compared the median fluorescence intensity of CD150 
expression, analysed as described in Figure 4.2.2, between exbreeder (3587618) and 
asplenic exbreeder mice (2764496). We did not observe a statistical difference between 















































































































































































Figure 4.2.4 Bone marrow HSC analysis in normal and asplenic exbreeder 
mice. 
 
Exbreeder C57BL/6J mice underwent at least six bouts of pregnancy and were 
approximately 9 months old. Asplenic exbreeder mice were splenectomised at 4-
weeks, and allowed to age and breed under the same conditions as the normal 
exbreeder control group. A) Bone marrow derived LT-HSC were gated according to 
Figure 4.1 to define CD150hi/lo/- expression. B) Median fluorescence intensity (MFI) 
of CD150 on LT-HSC from normal exbreeder (●) and asplenic exbreeder (■) mice. 
C) CD150+ LT-HSC number was calculated by multiplying the % LT-HSC by the 
number of live lineage-depleted bone marrow cells (exbreeder = grey; asplenic 
exbreeder = blue). D) The live lineage-depleted bone marrow count was used to 
estimate bone marrow (BM) cellularity for normal exbreeder (grey) and asplenic 
exbreeder (blue) mice. In this study, normal exbreeder (n=7) and asplenic exbreeder 
(n=5) mice were analysed in seven independent experiments. All error bars 
represent SEM. Data was first analysed for a Gaussian distribution using the 
Shapiro-Wilk normality test before either a one-way ANOVA with Sidak multiple 






The total number of CD150+ LT-HSC in bone marrow was calculated by multiplying 
the percentage of gated CD150+ LT-HSC by the live lineage-depleted bone marrow 
white cell count. The total CD150+ LT-HSC number in asplenic exbreeder mice 
showed a significant decrease of ~2.8 fold compared to normal exbreeders (Figure 
4.2.4C). Cellularity between the two groups was not different (Figure 4.2.4D) 
suggesting that the presence of spleen during pregnancy is essential for the 
expansion of CD150+LT-HSC and does not affect the overall bone marrow cellularity. 
Overall, these results do not support the hypothesis that splenic microenvironment 
contributes to age-associated myeloid-biased amongst HSC, assuming that HSC 








The isolation of LT-HSC has been achieved using different combinations of cell 
surface markers. In this study, markers were chosen by combining and adapting two 
methods previously published (Balazs et al., 2006; Beerman et al., 2010). For this 
study, it was necessary to identify LT-HSC on the basis of age-associated myeloid-
bias characterized by increased CD150 expression on LT-HSC (Beerman et al., 
2010). As with the Beerman et al. (2010) study, our marker panel included CD34 
and CD150 alongside the traditional LSK panel of markers used for enrichment. 
However, instead of FLT3, the marker panel included EPCR (CD201). EPCR has 
been described as a marker that identifies tissue endogenous HSC as well as a 
subset of LT-HSC (Balazs et al., 2006; Benz et al., 2012). Overall, this marker panel 
enabled investigation into whether HSC exposed to the splenic microenvironment 
contributed to overall age-associated increases in myeloid-biased CD150hi HSC.   
 
Myeloid-biased HSC are characterized by high CD150 expression, while low CD150 
expression is associated with a balanced differentiation potential (Beerman et al., 
2010; Morita et al., 2010). In this chapter, the frequency of CD150lo/hi HSC was 
assessed for each experimental group as in existing HSC studies (Beerman et al., 
2010; Dykstra, Olthof, Schreuder, Ritsema, & de Haan, 2011; Morita et al., 2010). 
Multiple limitations were identified with traditional CD150lo/hi population analysis, 
including inconsistency in gating between independent experiments which 
predisposes data to potential subjectivity during flow cytometry analyses (Lux et al., 
2018). This was compounded by the inclusion of antibodies against CD48 in the 
lineage depletion panel. Initially we analysed CD48 co-expression with a variety of 
common hematopoietic lineage markers (CD3, CD19, CD11a, CD11c, CD34, Gr-1 
and NK1.1) and found that CD48 was co-expressed with many lineage markers but 
not with Gr-1, NK1.1, CD11a and CD11c (Appendix A.8). For this reason, we 
included CD48 in the lineage depletion cocktail. We subsequently encountered 
limitations with this approach when establishing the CD150lo gate using an internal 
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Lineage-cKit+Sca-1- MEP control population. All MEP cells express CD48 (Draper et 
al., 2018). As a consequence, CD48 depletion impacted the number of these control 
cells and showed variability across preparations. We therefore standardized the 
event count for all internal control Lineage-cKit+Sca-1- populations and set the 
CD150lo gate to include 98% of events (Figure 4.2.1). This last step removed 
variability in gating CD150hi cells in the event of outliers. Given the difficulty 
associated with gating HSC populations, we also calculated the level of CD150 
expression amongst LT-HSC through assessment of MFI as an alternative method 
to detect age-associated HSC population change (Figure 4.2.2). This method 
allowed us to circumvent CD150 gating altogether, and to represent data in a more 
objective manner.  
 
Increased CD150 expression on LT-HSC is considered a defining characteristic of 
myeloid-biased HSC (Beerman et al., 2010). Old control animals in this study 
displayed a significantly larger proportion of CD150hi HSC compared with young 
control animals (Figure 4.2.3A), verifying that the ageing model was viable despite 
increased %LSK variation in old mice (Dykstra et al., 2011). While a significant 
increase in CD150hi HSC frequency was found between control young and control 
old animal groups (Figure 4.2.3A), no difference was found between young, old and 
old asplenic groups when CD150hi LT-HSC populations were compared (Figure 
4.2.3B). Furthermore, direct comparison of young versus old versus old asplenic 
mice against 12-month and 24-month data recalculated from Beerman et al. (2010) 
revealed striking similarities (Appendix A.9). However, it is important to note that 
neither the current nor previous study reported significant differences between any 
group. 
 
In addition, our model did not reproduce the reduction in CD150lo HSC number 
between young and old animals that was previously reported (Beerman et al., 2010; 
Morita et al., 2010). In our hands, this finding suggests that myeloid-biased CD150hi 




we did not detect a statistically significant decrease in CD150hi HSC in old asplenic 
animals compared with old normal animals. While this finding may be impacted by 
naturally higher variation amongst %LSK cells in older animals (Dykstra et al., 2011), 
in combination with CD150 MFI data (Figure 4.2.3C), our results suggest that the 
spleen does not contribute to an increase in myeloid-biased CD150hi HSC over a 
lifetime. 
 
In terms of HSC numbers, previous research has reported an expansion of CD150+ 
LT-HSC in older mice  (Dykstra et al., 2011; Sudo, Ema, Morita, & Nakauchi, 2000; 
Yamamoto et al., 2018). These reports suggest that young mice maintain strict 
control of the LSK CD34-EPCR+CD150+ pool size, whereas in old mice pool size 
varies (Dykstra et al., 2011). In this study, we observed no difference between 
normal young and old groups. This is also attributed to the reported high variability 
in HSC numbers observed in aged mice. This variability was seen here not only in 
the old group, but also in the old asplenic group, suggesting that a similar age-
associated lack of control exists in the old asplenic group (Figure 4.2.3D). The 
absence of a spleen did not impact the development of an expanded and variable 
HSC pool. 
 
Lastly, bone marrow cellularity did not differ significantly between young, old and old 
asplenic groups (Figure 4.2.3E). Although variability in bone marrow cell number 
was observed in all groups consistent with published data (Sudo et al., 2000), the 
cellularity of murine bone marrow does not vary with age (Sudo et al., 2000). Bone 
marrow cellularity was an important parameter in studying HSC numbers in normal 
and asplenic mice, to ensure that the absence of a spleen did not affect lineage- cell 
numbers in bone marrow over age. Because bone marrow cellularity remained 
consistent across all three treatment groups, the expansion of CD150+ LT-HSC 




Pregnancy was used as a model to induce extramedullary hematopoiesis in order to 
study whether multiple mobilization events phenotypically aged HSC through 
repeated exposure to the spleen environment. In comparison with normal exbreeder 
mice, we hypothesized that asplenic exbreeder mice would display a lower number 
of CD150hi HSC, and therefore a “younger” HSC phenotype. We note that the 
number of CD150lo HSC in asplenic exbreeder mice significantly increased by 
~15.4% above normal exbreeders (Figure 4.2.4A). While this was associated with 
a decrease in percentage of CD150hi HSC between asplenic and normal exbreeder 
mice, this was not significant (Figure 4.2.4A). In terms of MFI, CD150 expression 
on LT-HSC did decrease in aged exbreeder mice which had lost a spleen, but again 
this was not significantly different (Figure 4.2.4B), supporting findings from Figure 
4.2.3. The data available to date do not support the hypothesis that absence of a 
spleen during pregnancy contributes to changes in the HSC population in terms of 
CD150 expression. A retrospective power analysis of this experiment predicts that a 
sample size of 108 mice would be needed to show significance. 
 
In the absence of a spleen, and of pregnancy induced extramedullary hematopoiesis 
associated with spleen, a significant decrease in number of CD150+ LT-HSC in bone 
marrow of asplenic versus normal exbreeder mice was identified (Figure 4.2.4C). 
One explanation is that in the absence of a spleen, HSC would migrate from bone 
marrow in search of extramedullary sites, perhaps homing into organs which do not 
support hematopoiesis (Bowling et al., 2008). HSC that remain in bone marrow may 
expand within the limited confines of the bone marrows niche (Figure 4.2.4C), 
resulting in changes in the HSC population. The contribution of spleen is well known 
particularly for support of stress-induced extramedullary hematopoiesis. Previous 
studies have demonstrated the ability of spleen to induce a pre-activated cell-cycle 
state amongst HSC (Coppin et al., 2018), allowing faster proliferation of HSC to meet 
the  high demands that stress and pregnancy impose (Nakada et al., 2014; Oguro 
et al., 2017). A recent study suggested marker CD61 identified myeloid-biased LT-




Incorporating CD61 into future analyses of pregnancy-induced extramedullary 
hematopoiesis may allow better insight of the proportion of collected LT-HSC that 
were primed for, and contributed to, the cellular expansion within the spleen. Bone 
marrow cellularity was found to remain constant in normal and asplenic exbreeder 
mice (Figure 4.2.4D) consistent with results obtained through comparison of young, 
old and old asplenic mice (Figure 4.2.3D).  This is consistent with the cellular space 
in bone marrow being finite, compared with spleen where capacity for expansion is 
not restricted (Nakada et al., 2014).  
 
In our exbreeder study, an age-matched normal counterpart should ideally have 
been used as a control to determine whether LT-HSC number, bone marrow 
cellularity and CD150 expression differed between young and old, and between 
aged and exbreeder aged mice.  At this point, we cannot determine the impact of 
pregnancy on the aging phenotype. We can only conclude that the presence of a 
spleen is associated with higher CD150+ LT-HSC numbers in bone marrow, and may 
have slightly decreased the percentage of CD150lo or balanced LT-HSC in 
exbreeders. 
 
In summary, we used two animal models to investigate the role of spleen in the age-
related accumulation of myeloid-biased CD150hi HSC. Our ageing model first 
confirmed increases in number of CD150hi LT-HSC in control old mice compared 
with young counterparts. Subsequently, comparison between old and old asplenic 
mice did not show any statistical difference in number of CD150hi LT-HSC. Our 
second model involved exbreeder mice which had undergone multiple rounds of 
EMH triggered by pregnancy which would have mobilized HSC into the spleen with 
each pregnancy. In this model, no decrease in the number of CD150hi LT-HSC was 
observed in exbreeder mice which had been splenectomised ahead of pregnancy 
compared with normal exbreeders. Overall, the data indicate that spleen does not 
play a significant role in the progressive myeloid-biased HSC shift over the lifetime 
of an animal. According to previous studies, young and old animals are considered 
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statistically different. Immunophenotyping may be a limitation in this instance, 
contributing to the variation that deterred the young and old controls from being 
statistically different. Therefore, we suggest no firm conclusion can be drawn due to 
a high risk of a type II error present within our results. For future studies, a 
prospective sample size calculation should consider the high degree of variability 
that is commonly seen within the old age group and adjust the expected power 
accordingly. 
 
Analysis of aging based on differential CD150 expression introduces a gating bias 
and so results should be interpreted with caution. Furthermore, a recent study has 
suggested that CD150 may not accurately discriminate aged myeloid-biased HSC 
from the young counterpart (Kowalczyk et al., 2015). Using single cell RNA-seq 
technology has identified that cell cycle is a main source of transcriptional variation 
between HSCs populations as well as across young and old (Kowalczyk et al., 2015). 
Here we highlight the importance of future studies to consider using single cell RNA-
seq applications alongside our proposed phenotypic analysis for a truly robust 
analysis.  In future, a second marker for aging could be sought for use in conjunction 
with CD150 expression and CD41 is a possibility (Gekas & Graf, 2013). As with 
CD150, CD41 expression increases as HSC age. By using two positive markers for 
aging, analysis on the basis of MFI will remove any subjectivity during analysis. 
Further experiments are necessary for the pregnancy model, which will include an 
age-matched control to allow analysis of the role of spleen in specific age-related 
changes and a re-evaluation of necessary sample size and power to identify the 






















5.1 Introduction  
 
The spleen is known to support hematopoiesis, particularly during stress- or disease-
induced conditions. However, increasingly, research now indicates that the spleen 
plays a more significant role in hematopoietic regulation and aging than originally 
thought. Over a lifetime, long-term (LT)-HSC reportedly produce a shift in 
hematopoietic output, from balanced production of myeloid and lymphoid lineages 
typically associated with a ‘young’ phenotype, towards myeloid-biased production 
associated with aging (Beerman et al., 2010; Benz et al., 2012; Dykstra et al., 2007). 
Studies have proposed markers to distinguish balanced LT-HSC from myeloid-
biased LT-HSC with the most promising marker defined as CD150, a member of the 
signaling lymphocyte activation molecule (SLAM) family (Morita et al., 2010; Oguro 
et al., 2013). Several previous studies report effective distinction of LT-HSC through 
differential expression of CD150, with LT-HSC showing balanced lineage potential 
identifiable as CD150lo cells and myeloid-biased LT-HSC identified as CD150hi cells 
(Beerman et al., 2010; Dykstra et al., 2011; Morita et al., 2010).  
 
The spleen now identifies as a prominent site for extramedullary hematopoiesis (Inra 
et al., 2015; Robbins et al., 2012; Wilkins, Green, Wild, & Jones, 1994).  However, 
spleen hematopoietic involvement during the steady-state condition has evaded 
rigorous study in the face of so many bone marrow studies. Stem cell migration is in 
constant flux and is evident by the presence of HSC in the peripheral blood at any 
given moment (Wright et al., 2001). HSC migration functions as an important 
component of systemic hematopoietic homeostasis. HSC migration mediates HSC 
redistribution which ensures bone marrow niches are not left unoccupied and 
functions as an immediate means of extramedullary recruitment in the event of stress 
(Wright et al., 2001).  
 
The work in this thesis aimed firstly, to determine the steady-state lineage output of 





to age-related myeloid-biased HSC differentiation. A novel diet-based 
transplantation preconditioning treatment is optimized for further use in 
characterizing spleen endogenous hematopoietic output under steady-state 
conditions. We have shown that valine availability at the time of transplantation 
determines donor-chimerism success. We found that reintroduction of valine two 
days prior to transplantation increased engraftment success. Furthermore, this 
thesis focused on identifying the contribution of spleen to myelopoietic dominance in 
old age. We designed an animal model to accelerate the effects of splenic influence 
during aging. This required only a third of the time to induce aged-associated 
hematopoietic change. This study showed that the spleen does not contribute to 
increases in myeloid-biased CD150hi HSC over a lifetime. Several limitations in 
analysis were noted in these experiments which hampered a firm conclusion. 
Reporting median fluorescence intensity of CD150 expression was found to be a 
more robust measurement of expression changes between aging groups than the 




Dietary-based preconditioning methods offer a fresh approach compared with 
traditional transplantation preconditioning methods that are the gold standard 
practice in patients suffering from myeloproliferative diseases such as leukemia. 
Recently, valine-depletion was shown to be a viable method for clearing the HSC 
niche in preparation for hematopoietic transplantation (Taya et al., 2016). The most 
notable feature of this dietary-based conditioning treatment was its complete 
reversibility, with recipients returning to full health once complete diet was reinstated. 
Here, we assess the viability of this, not only to condition the host HSC niche space, 
but to critically analyse valine-restriction as preconditioning treatment which 






Experiments were designed to optimize the valine-depletion method (Taya et al., 
2016), but confirmed that valine depletion did not completely clear the niche of HSC 
like irradiation treatment. However, mixed reports have been published regarding 
the necessity of complete preconditioning for donor engraftment, with some studies 
reporting donor engraftment in unconditioned hosts (Bhattacharya et al., 2006; 
Ramshaw et al., 1995; Stewart et al., 1993; Westerhuis et al., 2011). In terms of a 
preconditioning method aimed at replacing ablative therapies in human allogeneic 
transplantation, incomplete niche clearance is one factor associated with increased 
risk of donor rejection (Mengarelli et al., 2002).  
 
Chapter 3 investigates this novel valine depletion preconditioning approach, 
optimizes the method to enhance its capacity to clear HSC from the niche and to 
engraft donor cells for long- and short-term lineage reconstitution analysis. 
Experiments performed here confirm that valine restriction effectively depletes HSC 
from the host, and valine reintroduction reverses the ablative effects similar to the 
findings reported by Taya et al. (2016).  In addition to demonstrating bone marrow 
clearance, our study confirms that the splenic niche is also cleared of HSC, which 
has not previously been shown. 
 
Next, it was important to test the capacity for HSC to migrate into niche space cleared 
by valine restriction. Considering valine’s demonstrated importance in HSC-niche 
interactions, we tested whether donor cell migration could be detected in the host 
within a few hours after refeeding was commenced. Valine depleted mice were 
considerably lethargic and weak. Upon return to a complete diet, mice did not begin 
to eat for a short while, adding a limitation to the use of the valine-restricted 
preconditioning approach for homing assays of less than 18 hours. A 48-hour 
homing analysis of transplanted splenocytes revealed donor chimerism in the 
peripheral blood and spleen but not in bone marrow. While it is difficult to draw 
conclusions from the findings of a single experiment, it is thought that this result is 





detection of unfractioned donor splenocytes, but also supports differential homing of 
tissue-specific cell populations (Szilvassy et al., 1999; Szilvassy, Meyerrose, 
Ragland, & Grimes, 2001).  
 
The long-term engraftment assay was set up at the same time as the homing 
analysis with transplantation of lineage depleted bone marrow cells. Donor cell 
engraftment was not evident in both the bone marrow and spleen tissue of the host. 
Two days of valine refeeding prior to transplantation resulted in better engraftment, 
and showed that graft success relied largely on availability of valine at the time of 
transplantation. Lineage characterization at 4 weeks after transplantation from mice 
refed 2-days prior to transplant, identified similar B cell and myeloid cell 
reconstitution as unconditioned controls, with recovery to the levels reported by Taya 
et al. (2016). However, we were still unable to achieve donor chimerism levels 
comparable with that shown in the original report (Taya et al., 2016). This raises the 
question of whether remaining host-type cells have an advantage over donor-type 
cells in the race to occupy niche space as the biological concentration of valine 
increases.  
 
In the normal mouse, ~0.1%-1% of HSC niches are available for engraftment at any 
time (Bhattacharya et al., 2006). In the mouse preconditioned through valine-
restriction, ~10% donor chimerism is maintained by 12-weeks after transplantation 
(Taya et al., 2016). It is difficult to determine whether the cell dose given was 
insufficient to support hematopoietic reconstitution, or whether valine-restriction 
prevented donor cells from competing effectively with host type cells. Optimization 
of several parameters including cell dosage, donor cell capacity for LT- and ST-
reconstitution and niche viability during the reintroduction phase, will be necessary 
in order to develop a complete understanding of the impact of valine-depletion on 
the HSC niche. Further understanding will ultimately dictate the validity of this 








HSC in murine spleen are rare and phenotypically different to bone marrow HSC 
(Coppin et al., 2018). The spleen has been studied primarily for its contribution to 
hematopoiesis under stress situations, otherwise known as extramedullary 
hematopoiesis (Inra et al., 2015). Several studies report that the spleen contributes 
to myelopoiesis and erythropoiesis during extramedullary hematopoiesis (Inra et al., 
2015; Mumau et al., 2018; Nakada et al., 2014; Tan & O'Neill, 2012; Yanai et al., 
1991). The microenvironment of spleen and bone marrow  differ, and evidence is 
emerging to suggest that the splenic niche impacts HSC both intrinsically and 
extrinsically (Coppin et al., 2018; Morita et al., 2011). An understanding of how the 
spleen contributes to hematopoiesis in the steady-state condition is important in 
terms of finding a mechanism for the age-associated decline of a balanced myeloid 
and lymphoid lineage output (Beerman et al., 2010). Ultimately this imbalance leads 
to increased prevalence of myeloproliferative diseases and deterioration of the 
adaptive immune system in the elderly (Lichtman & Rowe, 2004).  
 
HSC primarily reside in bone marrow. However they migrate under normal 
conditions, evident by a constant flux of HSC in the peripheral blood (Wright et al., 
2001). Researchers speculate that this constant reshuffling acts to maintain 
occupation of niche space during the constant turnover of HSC (Goodman & 
Hodgson, 1962; Wright et al., 2001). Comparison of the physiological migratory 
patterns of HSC over the duration of an animal’s life in the absence and presence of 
the spleen has been a major aim of this study in order to identify whether the constant 
shuffling of HSC, i.e. exposing HSC to the spleen multiple times in a lifetime, has an 
impact on the progression of the myeloid-biased aging phenomenon. 
 
In Chapter 4, two experimental models of aging were investigated based on the 
presence and absence of a spleen during a murine lifetime. The first model was 





phenotype in normal young and old mice and in old asplenic mice. The second model 
involved exbreeders as a model to accelerate the effects of HSC aging by eliciting 
multiple bouts of pregnancy-induced extramedullary hematopoiesis. It is intended 
that this might exacerbate the migration of HSC towards the spleen, and so subject 
large quantities of HSC to the splenic niche and its possible myelopoietic effects. 
This study therefore directly compared the HSC phenotypic ‘age’ of exbreeders with 
and without a spleen.  
 
Increasing expression of CD150 correlates with increasing HSC age (Beerman et 
al., 2010) and myeloid-biased differentiation capacity (Morita et al., 2010). This study 
has shown that cell surface expression of CD150 does not vary between aged 
normal and aged asplenic mice. The current field analyzes changes in CD150 
expression on LT-HSC by comparing three cell fractions; CD150hi, CD150lo and 
CD150. When CD150- cells were included within the LT-HSC subset analysis, 
accumulation of CD150hi cells with age was found not to be inversely related to a 
decline in the number of CD150lo cells.  Therefore, we reasoned that CD150hi LT-
HSC cells should be assessed for myeloid-bias based on the proportion of CD150hi 
cells amongst all CD150+ cells. Through exclusion of the CD150- fraction, the inverse 
relationship of myeloid-biased and balanced phenotypes could be distinguished. 
Indeed, a more robust measurement of expression changes is achieved through 
comparison of median fluorescence intensity. However comparative studies by 
others have not reported such data.  
 
Findings reported here suggest that there is no difference between LT-HSC in bone 
marrow of young, old and old asplenic mice, despite a growing consensus amongst 
researchers in the field that young bone marrow-derived LT-HSC are phenotypically 
more balanced (CD150lo) than old LT-HSC, which are associated with increased 
myeloid-bias (CD150hi). While we did demonstrate significant differences between 
young and old in terms of %CD150hi LT-HSC (when CD150- was included), we did 





is expected to have an inverse relationship to CD150hi HSC. When data from a 
previously published study (Beerman et al., 2010) is recalculated to remove the 
CD150- expressing HSC fraction, our data for young and old asplenic mice both 
closely resembles 12-month old (midaged) mice and our old mice resemble 24-
month old (old aged) mice from the Beerman et al. (2010) study. This comparison 
between studies supports that the absence of a spleen over a lifetime restricts 
myeloid-biased hematopoietic accumulation on the basis of CD150+ expression. 
However, from CD150 MFI data, it cannot be statistically concluded that the absence 
of a spleen restricts myeloid-bias expansion over age. 
 
Pregnancy-induced extramedullary hematopoiesis did not accelerate the effects of 
aging. Splenectomised mice were not statistically distinct from normal mice in terms 
of CD150 phenotype of LT-HSC. This finding suggests that an increased flux of 
migrating HSC towards spleen did not have an impact on aging phenotype in LT-
HSC. Here we conclude that intrinsic forces of cell aging are more powerful than the 
extrinsic contribution of the spleen niche. One particular limitation to our study has 
been the absence of an age-matched 9-month-old control counterpart. This 
treatment group would have allowed the exbreeder data to be directly compared to 
a naturally aging group. 
 
Future experiments will utilize CD150+ expression to delineate age-associated 
changes in animals. Furthermore, the inclusion of CD41 and CD61 within future 
immunophenotyping analysis will help to delineate myeloid-bias within the LT-HSC 
subset (Mann et al., 2018; Gekas & Graf, 2013). Additionally, RNA-seq may be used 
more specifically to identify intrinsic changes at the single-cell level, providing a 
deeper insight into clonal distribution develops over age and the exact mechanisms 
responsible for these changes (Kowalczyk et al., 2015). The spleen has been shown 
to support myelopoiesis in several studies (Coppin et al., 2018; Morita et al., 2011; 
Slayton et al., 2002; Tan & O'Neill, 2010; Wu et al., 2018). It is difficult to understand 





2002) in the steady-state condition, and is cycled into the migratory system and 
replaced (Wright et al., 2001), would contribute to myeloid-biased-associated aging 
on a long-term scale. 
 
In conclusion, this study has optimized a dietary-mediated approach to 
preconditioning, which supports the steady-state condition. Spleen-specific 
hematopoiesis has not yet been studied in the steady-state condition, but can now 
be explored. The spleen did not contribute to the age-associated myeloid-biased 
progression over age in this study. However, it is not possible to draw firm 
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CD150-/+ gate Live selection 




A.1 Lineage depleted bone marrow or spleen was stained with fluorochrome 
conjugated antibodies as outlined in Figure 4.2.1. Cells were analysed by flow 
cytometry for the LSKCD34-CD150+ EPCR+ phenotype using antibodies specific for 
cKit (2B8; FITC), Sca-1 (D7; BV421), CD150 (mSHAD150; PE-Cy7), CD34 (RAM34; 
eFluor 660) and CD201 (eBio1560; PE). Streptavidin (SA)-APC-eFluor 780 was 
used as a secondary reagent to detect any remaining undepleted lineage+ cells. Prior 
to flow cytometry, cells were stained with propidium iodine (PI-) to include only PI- 
viable cells in further analyses. Gating strategy identifies the gating criteria for LT-
HSC and defines CD150+/- boundaries. Percent positive cells is indicated in each 
plot. Specific gates for CD34- and CD150- were set based on forward minus one 
controls (FMOC). Final plot displays events using a ‘smoothing’ feature with outlier’s 
present. All HSC analyses of valine-depleted animals follows this gating strategy and 




Appendix A.2 Spleen destruction 
 
  




A.2  A spleen injected with an ultrafine 0.2mL needle and an untreated spleen 
were frozen and cryo-sectioned into 71µm thick sections for analysis. Spleen 
sections were fixed with acetone for 5 minutes at room temperature and then washed 
three times in PBS. Each tissue section was first blocked with FcBlock (CD16/32; 
clone 93) before primary antibodies for CD105 (MJ7/18; PE) and ER-TR7 (SC-
73355; af488) were used. Images were captured using Nikon Live Cell Ti2 
Microscope and processed using ImageJ FIJI software. First image row is the 
untreated spleen and the following two rows show tissue damage from serial 





Appendix A.3 Control gating for homing analysis 
 
 
A.3 Donor CD45.2+DIR+ gates were set using B6.SJL as a control. A) Bone 
marrow (BM), peripheral blood (PB) and spleen (SPL) were analysed. Dot plots 
display a standardized number of events (5578). B) The F4/80+ gate was set using 
an F4/80 forward minus one control (FMOC) and a complete antibody mix on 












































































































































BM PB SPL 






































































































































C57BL/6 BM  
F4/80 FMOC 






Appendix A.4 Percentage of B cells amongst whole spleen leukocytes 
 
 
A.4 The percentage of B cells amongst whole spleen leukocytes were identified 
as the final gated percentage of single live B220+CD19+ expressing cells from a 2-
month-old C57BL/6J mice (donor type).  





























































C57BL/6 B cell sort. 
600,000 cells sorted
C57BL/6 B cell sort purity check
cells
96.2













































































































































































A.5 Donor gating for long-term and short-term reconstitution. A) Bone marrow of 
untreated B6.SJL and C57BL/6J mice were stained for CD45.1 and CD45.2 (donor 
marker). A mix of bone marrow from both C57BL/6J mice and B6.SJL mice was 
analysed as a positive control, alongside the C57BL/6J (donor type) only sample. 
B6.SJL mice were used as the host type and used as a negative control for CD45.2+ 
gating. Background CD45.2+ (donor expression) never exceeded 0.03%, therefore 
treatment samples were positive for donor chimerism when the percentage of donor 
marker was >0.1%. B) Lineage reconstitution analysis for -1 and -2 day refeed before 
transplant groups and control groups are examined for B (B220+), T (CD5+) and 
myeloid (CD11b+ & CD11c+) cell expression. C57BL/6J control lineage percentages 




























































































































































































































































































































































































































































































































































B & T cell








Appendix A.6 Influence of valine on lineage- cell count and calculating LSK frequency within 













































































A.6A Bone marrow and spleen were homogenized, RBC lysed and single cell 
strained before magnetic depletion of lineage+ cells. Lineage depleted bone marrow 
or spleen of valine restricted mice or control mice that were maintained on complete 
diet were stained with trypan blue (1:4 dilution) and counted using a hemocytometer. 
The graph shows number of lineage depleted cells in bone marrow and spleen of 
mice fed valine-restricted diet or complete diet after a 3-week valine depletion phase. 
Statistical significance was tested using an unpaired Student’s t-test. Statistical 
significance is indicated when (**) P<0.005 and (*) P<0.05. 
 
 
A.6B Calculating the frequency of LSK within a lineage depleted fraction of either 
bone marrow or spleen cells to identify the number of LSK within a transplant of 
lineage depleted bone marrow or spleen leukocytes. The absolute percentage of 
LSK cells were determined by multiplying the gated percentage of lineage- cells by 
the gated percentage of cKit+Sca-1+ cells (represented in graph). The absolute 
percentage can then be multiplied by the number of lineage depleted cells to identify 






















A.7 An untreated control spleen (left) and a valine-restricted spleen (right) from 
11-week old mice depicts the degree of atrophy in the spleen after 3-weeks of valine 
restriction. The spleen from valine-restricted mice is noticeably smaller than mice 
that were fed a complete diet. These observations were consistent between all mice 













A.8 To isolate HSC, a cell suspension must first be enriched for rare 
progenitor populations. This step facilitates the sorting for HSC as Lin-Sca-
1+cKit+CD150+CD48-CD34-EPCR+ cells, which can then be used for in vivo 
transplantation assays and LT-HSC analysis. Lineage depletion requires 
multiple antibodies in order to deplete mature cell lineages from the desired LT-
HSC population. Cells from both bone marrow (top row) and spleen (middle row) 
were analysed for co-expression of CD48 with mature lineage markers. Co-
expression is denoted by events in the top right quadrant of a plot. An unstained 
control is displayed on the bottom row. CD48 co-expression is exhibited for all 
antibodies except CD11a, CD11c, Gr-1 and NK1.1. Therefore, the lineage 
depletion cocktail used for all LT-HSC enrichment was CD48, CD11c, Gr-1, 
NK1.1 as well as Fc Block (CD16/32). CD11a was not included due to cost 







































A.9 CD150hi LT-HSC calculated from Figure 3D of the Beerman et al. (2010) 
study; ‘Functionally distinct hematopoietic stem cells modulate hematopoietic 
lineage potential during aging by a mechanism of clonal expansion’. To compare 
CD150+ expression frequencies from the published study to our own data, we 
transformed (T) the reported CD150-, CD150lo and CD150hi values to exclude 




(CD150hi +  CD150lo) 
× 100 
 
Since CD150hi and CD150lo are inversely related, we represent only CD150hi 
percentages from 4-month-old (4m), 12-month-old (12m) and 24-month-old 
(24m) mice. The CD150 populations were originally gated within the LSKCD34-
flt3- compartment. The data adapted from Beerman et al. (2010) were averaged 
























Appendix A.10 Supplier addresses 
Source Location 
ARC Perth, WA, Australia 
Darvall Vet Gladesville ,NSW, Australia 
Biolegend San Diego, CA, USA 
Bio-rad Hercules, CA, USA 
Beckton Dickinson San Jose, CA, USA 
Corning Inc. Corning, NY, USA 
Cosmo Bio Tokyo, Japan 
eBioscience San Diego, CA, USA 
Ethicon Inc. Somerville, NJ, USA 
Fisher Scientific Hampton, NH, USA 
FlowJo Ashland, OR, USA 
GraphPad Software San Diego, CA, USA 
Greiner Bio-One Kremsmunster, Austria 
InstrumeC Victoria, Australia 
Kimberly-Clark Irving, TX, USA 
LOCI Maddison, WI, USA 
Leica Microsystems Wetzlar, Germany 
Livingstone International Toronto, Canada 
Miltenyi Biotec Gladbach, Germany 
Research Diets Inc. New Brunswick, NJ, USA 
Sakura Finetek Tokyo, Japan 
Santa Cruz Biotechnology Dallas, TX, USA 
Sigma-Aldrich St. Louis, MO, USA 
StemCell Technologies Vancouver, Canada 
Terumo Tokyo, Japan 
ThermoFischer Victoria, Australia 
Thomas Scientific Swedesboro, NJ, USA 
 
